

10/816,143

=> file registry

FILE 'REGISTRY' ENTERED AT 14:03:31 ON 30 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 MAR 2007 HIGHEST RN 928707-03-3

DICTIONARY FILE UPDATES: 29 MAR 2007 HIGHEST RN 928707-03-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> file caplus

FILE 'CAPLUS' ENTERED AT 14:03:34 ON 30 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Mar 2007 VOL 146 ISS 15

FILE LAST UPDATED: 29 Mar 2007 (20070329/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:


<http://www.cas.org/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d stat que L15



L10	123	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	SCHINDLER U?/AU
L11	7	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	SCHONAFINGER K?/AU
L12	315	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	STROBEL H?/AU
L13	15	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	L10 AND (L11 OR L12)
L14	3	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	L11 AND L12
L15	15	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	(L13 OR L14)

=> d stat que L16
L3 STR



G1 [@1],[@2]

Structure attributes must be viewed using STN Express query preparation:
Uploading L3.str



chain nodes :
16 20 21
ring nodes :
1 2 3 4 5 6 15
ring/chain nodes :
7 8 9 13 14 17
chain bonds :

4-7 5-20 15-16 20-21
 ring/chain bonds :
 7-13 7-14 14-17 15-17
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 exact/norm bonds :
 4-7 5-20 7-13 7-14 14-17 15-16 15-17 20-21
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 13:CLASS
 14:CLASS 15:Atom 16:CLASS 17:CLASS 20:CLASS 21:CLASS

L6 512 SEA FILE=REGISTRY SSS FUL L3
 L7 56 SEA FILE=CAPLUS ABB=ON PLU=ON L6
 L10 123 SEA FILE=CAPLUS ABB=ON PLU=ON SCHINDLER U?/AU
 L11 7 SEA FILE=CAPLUS ABB=ON PLU=ON SCHONAFINGER K?/AU
 L12 315 SEA FILE=CAPLUS ABB=ON PLU=ON STROBEL H?/AU
 L16 4 SEA FILE=CAPLUS ABB=ON PLU=ON (L10 OR L11 OR L12) AND L7

=> s L15-l16

L33 15 (L15 OR L16)

=> d ide L29

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

L29 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 254877-03-7 REGISTRY


ED Entered STN: 04 Feb 2000

CN Benzamide, 5-chloro-2-[[[4-chlorophenyl)sulfonyl]amino]-N-[4-methyl-5-(4-thiomorpholinylsulfonyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)

MF C21 H20 Cl2 N4 O5 S4

SR CA

LC STN Files: CA, CAPLUS, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s L29 and L33
2 L29
L34 2 L29 AND L33

=> d ibib abs hitrn L33 1-15

L33 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:336462 CAPLUS Full-text

DOCUMENT NUMBER: 145:20807

TITLE: Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase

AUTHOR(S): **Schindler, Ursula; Strobel, Hartmut**
; Schoenafinger, Karl; Linz, Wolfgang; Loehn, Matthias; Martorana, Piero A.; Ruetten, Hartmut; Schindler, Peter W.; Busch, Andreas E.; Sohn, Michael; Toepfer, Andrea; Pistorius, Astrid; Jannek, Christoph; Muelsch, Alexander

CORPORATE SOURCE: Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany

SOURCE: Molecular Pharmacology (2006), 69(4), 1260-1268

CODEN: MOPMA3; ISSN: 0026-895X

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The heme-enzyme soluble guanylyl cyclase (sGC) is an ubiquitous NO receptor, which mediates NO downstream signaling by the generation of cGMP. We studied the mechanism of action of the anthranilic acid derivs. 5-chloro-2-(5-chloro-thiophene)-2-sulfonylamino-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide sodium salt (HMR1766) (proposed international nonproprietary name, ataciguat sodium) and 2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide (S3448) as a new class of sGC agonists. Both compds. activated different sGC prepns. (purified from bovine lung, or crude from human corpus cavernosum) in a concentration-dependent and quickly reversible fashion ($EC_{50} = 0.5-10 \mu M$), with mixed-type activation kinetics. Activation of sGC by these compds. was additive to activation by NO donors, but instead of being inhibited, it was potentiated by the heme-iron oxidants 1H-[1,2,4]-oxdiazolo[3,4-a]quinoxalin-1-one (ODQ) and 4H-8-bromo-1,2,4-oxadiazolo(3,4-d) benz(b)(1,4)oxazin-1-one (NS2028), suggesting that the new compds. target the ferric heme sGC isoform. Protoporphyrin IX acted as a competitive activator, and zinc-protoporphyrin IX inhibited activation of heme-oxidized sGC by HMR1766 and S3448, whereas heme depletion of sGC by Tween 20 treatment reduced activation. Both compds. increased cGMP levels in cultured rat aortic smooth muscle cells; induced vasorelaxation of isolated endothelium-denuded rat aorta, porcine coronary arteries, and human corpus cavernosum ($EC_{50} 1$ to $10 \mu M$); and elicited phosphorylation of the cGMP kinase substrate vasodilator-stimulated phosphoprotein at Ser239. HMR1766 i.v. bolus injection decreased arterial blood pressure in anesthetized pigs. All of these pharmacol. responses to the new compds. were enhanced by ODQ and NS2028. Our findings suggest that HMR1766 and S3448 preferentially activate the NO-insensitive heme-oxidized form of sGC, which exists to a variable extent in vascular tissues, and is a pharmacol. target for these new vasodilator drugs.

IT 254877-04-8, S 3448 254877-67-3, HMR1766

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(biochem. and pharmacol. of novel anthranilic acid derivs. activating
heme-oxidized soluble guanylyl cyclase)

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:208446 CAPLUS Full-text
DOCUMENT NUMBER: 134:233614
TITLE: Method for the detection of oxidized forms of soluble
guanylate cyclase and for screening substances that
stimulate the activation of soluble guanylate cyclase
with oxidized heme iron
INVENTOR(S): **Schindler, Ursula; Strobel, Hartmut**
; Schindler, Peter
PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001020023	A2	20010322	WO 2000-EP8102	20000819
WO 2001020023	A3	20011115		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19944226	A1	20010329	DE 1999-19944226	19990915
CA 2382488	A1	20010322	CA 2000-2382488	20000819
BR 2000014019	A	20020521	BR 2000-14019	20000819
EP 1218535	A2	20020703	EP 2000-956466	20000819
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509061	T	20030311	JP 2001-523794	20000819
NZ 517783	A	20040625	NZ 2000-517783	20000819
AU 783268	B2	20051006	AU 2000-68396	20000819
AT 311473	T	20051215	AT 2000-956466	20000819
ES 2252046	T3	20060516	ES 2000-956466	20000819
US 6500631	B1	20021231	US 2000-661915	20000914
NO 2002001196	A	20020311	NO 2002-1196	20020311
ZA 2002002025	A	20040226	ZA 2002-2025	20020312
IN 2002CN00378	A	20070223	IN 2002-CN378	20020312
US 2003054433	A1	20030320	US 2002-268533	20021010
US 6913898	B2	20050705		
US 2005227308	A1	20051013	US 2005-144265	20050603
PRIORITY APPLN. INFO.:				
			DE 1999-19944226	A 19990915
			WO 2000-EP8102	W 20000819
			US 2000-661915	A3 20000914
			US 2002-268533	A3 20021010

AB The invention relates to a method for the detection of a soluble guanylate cyclase, whose heme iron is present in a trivalent oxidation state and a method for detecting chemical substances which stimulate the activity of soluble guanylate cyclase when said heme iron present in soluble guanylate cyclase is at least in part trivalently oxidized. The invention also relates to a diagnostic agent for detecting a soluble guanylate cyclase containing trivalent heme iron. The synthesis of 2-[[[4-chlorophenyl)sulfonyl]amino]-4,5- dimethoxy-N-[4-(4-thiomorpholinylsulfonyl)phenyl]benzamide is described that stimulates the activity of the oxidized forms of soluble guanylate cyclase and that of the heme-free enzyme.

IT **254877-04-8P**

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process) (method for detection of oxidized forms of soluble guanylate cyclase and for screening substances that stimulate activation of soluble guanylate cyclase with oxidized heme iron)

IT **254878-45-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (method for detection of oxidized forms of soluble guanylate cyclase and for screening substances that stimulate activation of soluble guanylate cyclase with oxidized heme iron)

L33 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:553569 CAPLUS Full-text

DOCUMENT NUMBER: 133:150575

TITLE: Preparation of substituted 4-amino-2-aryltetrahydroquinazolines as activators of soluble guanylate cyclase

INVENTOR(S): **Schindler, Ursula; Schonafinger, Karl; Strobel, Hartmut**

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2000046214	A1	20000810	WO 2000-EP468	20000122
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
DE 19904710	A1	20000810	DE 1999-19904710	19990205
CA 2362363	A1	20000810	CA 2000-2362363	20000122
EP 1150963	A1	20011107	EP 2000-901586	20000122
EP 1150963	B1	20031203		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002536369	T	20021029	JP 2000-597284	20000122
AT 255565	T	20031215	AT 2000-901586	20000122
PT 1150963	T	20040430	PT 2000-901586	20000122

ES 2211503	T3	20040716	ES 2000-901586	20000122
US 6660746	B1	20031209	US 2000-497723	20000204
US 2004063690	A1	20040401	US 2003-674350	20031001
US 7045526	B2	20060516		

PRIORITY APPLN. INFO.: DE 1999-19904710 A 19990205
WO 2000-EP468 W 20000122
US 2000-497723 A3 20000204

OTHER SOURCE(S): MARPAT 133:150575
GI




AB The title compds. [I; R1, R2 = H, (un)substituted alkyl, cycloalkyl, etc.; NR1R2 = (un)substituted 5-7 membered saturated heterocyclyl which can contain one further hetero atom selected from O, S, SO, SO2; R3 = aryl, but cannot be unsubstituted Ph] and their salts which have the ability to modulate the endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of disease states which are associated with a disturbed cGMP balance, for example, cardiovascular disorders such as high blood pressure, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis, were prepared. Thus, reacting 2-(4-chlorophenyl)-4-chloro-5,6,7,8-tetrahydroquinazoline (preparation given) with trans-4-aminocyclohexanol hydrochloride in the presence of tert-BuOK and N-methylpyrrolidine afforded (trans)-I.MeSO3H [R1 = trans-4-hydroxycyclohexylamino; R2 = H; R3 = 4-ClC6H4] which showed 28-fold stimulation of the sGC activity at 50 µM.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:349092 CAPLUS Full-text
DOCUMENT NUMBER: 132:347580
TITLE: 4-Amino-2-arylcyclopenta[d]pyrimidines and their use in treatment of diseases associated with cyclic guanosine monophosphate production
INVENTOR(S): **Schindler, Ursula**; Schoenafinger, Karl;
Strobel, Hartmut
PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany
SOURCE: Ger. Offen., 16 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19853278	A1	20000525	DE 1998-19853278	19981119

CA 2351488	A1	20000602	CA 1999-2351488	19991103
WO 2000031047	A1	20000602	WO 1999-EP8382	19991103
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1131302	A1	20010912	EP 1999-972626	19991103
EP 1131302	B1	20060201		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
JP 2002530385	T	20020917	JP 2000-583875	19991103
AT 316964	T	20060215	AT 1999-972626	19991103
PT 1131302	T	20060531	PT 1999-972626	19991103
ES 2257103	T3	20060716	ES 1999-972626	19991103
US 6627628	B1	20030930	US 2001-856069	20010517
US 2004048850	A1	20040311	US 2003-660489	20030912
US 7138398	B2	20061121		
PRIORITY APPLN. INFO.:			DE 1998-19853278	A 19981119
			WO 1999-EP8382	W 19991103
			US 2001-856069	A3 20010517
OTHER SOURCE(S):			MARPAT 132:347580	
GI				




AB Title compds. such as I [R = cyclopentylamino, morpholino, Et₂N, HOCH₂CH₂NH, BuNH, (3-pyridylmethyl)amino; R₁ = substituted phenyl] were prepared for therapy and prophylaxis of diseases like angina pectoris and thrombosis. Thus, I (R = OH, R₁ = 4-chlorophenyl) was prepared from Me 2-oxocyclopentanecarboxylate and 4-chlorobenzamidine hydrochloride and was treated with POCl₃ to give I (R = Cl, R₁ = 4-chlorophenyl), which (0.265 g) reacted with 0.4 g cyclopentylamine in 1 mL N-methylpyrrolidone 5 h at 130° to give 0.26 g I (R = cyclopentylamino, R₁ = 4-chlorophenyl). Several products were tested for activation of soluble guanylate cyclase, which catalyzes the conversion of guanosine triphosphate to cyclic guanosine monophosphate.

L33 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:115763 CAPLUS Full-text
 DOCUMENT NUMBER: 132:151833
 TITLE: Preparation of 4-amino-2-arylpyrimidines as modulators of cyclic guanosine monophosphate production.
 INVENTOR(S): **Schindler, Ursula**; Schoenafinger, Karl;
Strobel, Hartmut
 PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany
 SOURCE: Ger. Offen., 22 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent

LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19836697	A1	20000217	DE 1998-19836697	19980813
CA 2340405	A1	20000224	CA 1999-2340405	19990804
WO 2000009496	A1	20000224	WO 1999-EP5636	19990804
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9957307	A1	20000306	AU 1999-57307	19990804
AU 760988	B2	20030529		
BR 9913003	A	20010508	BR 1999-13003	19990804
EP 1112266	A1	20010704	EP 1999-944330	19990804
EP 1112266	B1	20030514		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002522536	T	20020723	JP 2000-564948	19990804
AT 240315	T	20030515	AT 1999-944330	19990804
PT 1112266	T	20030930	PT 1999-944330	19990804
ES 2196849	T3	20031216	ES 1999-944330	19990804
US 6844347	B1	20050118	US 2001-762893	20010213
PRIORITY APPLN. INFO.:			DE 1998-19836697	A 19980813
			WO 1999-EP5636	W 19990804
OTHER SOURCE(S):		MARPAT 132:151833		
GI				



AB Title compds. [I; R1 = (substituted) alkyl, cycloalkyl, 5-7 membered heterocyclyl; R2 = H, (substituted) alkyl, cycloalkyl, 5-7 membered heterocyclyl; R1R2N = (substituted) 5-7 membered heterocyclyl; R3 = aryl; R4 = alkyl, CF3, aryl], were prepared Thus, 4-chloro-2(4-chlorophenyl)-6-isopropylpyrimidine (preparation given) and 4-amino-2,2,6,6,-tetramethylpiperidine were stirred at 150° for 2 h to give 2-(4-chlorophenyl)-6-isopropyl-4-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidine dihydrochloride. Tested I at 50 µM stimulated guanylate cyclase by >4 to 28-fold.

TITLE: Preparation of sulfur substituted
sulfonylaminocarboxylic acid N-arylamides as
modulators of cyclic guanosine monophosphate (cGMP)
production

INVENTOR(S): **Schindler, Ursula; Schonafinger,
Karl; Strobel, Hartmut**

PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000002851	A1	20000120	WO 1999-EP4426	19990625
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19830430	A1	20000113	DE 1998-19830430	19980708
DE 19903126	A1	20000803	DE 1999-19903126	19990127
CA 2336807	A1	20000120	CA 1999-2336807	19990625
AU 9946160	A	20000201	AU 1999-46160	19990625
AU 761983	B2	20030612		
BR 9911914	A	20010327	BR 1999-11914	19990625
EP 1095016	A1	20010502	EP 1999-929318	19990625
EP 1095016	B1	20051109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002520309	T	20020709	JP 2000-559082	19990625
JP 3786579	B2	20060614		
RU 2234497	C2	20040820	RU 2001-103645	19990625
AT 309206	T	20051115	AT 1999-929318	19990625
NO 2001000013	A	20010301	NO 2001-13	20010102
IN 2001CN00029	A	20050304	IN 2001-CN29	20010108
PRIORITY APPLN. INFO.:			DE 1998-19830430	A 19980708
			DE 1999-19903126	A 19990127
			WO 1999-EP4426	W 19990625
OTHER SOURCE(S):	MARPAT 132:93104			
GI				



AB The title compds. [I; A1 = (un)substituted phenylene, naphthylene, heteroarylene; ring A2 comprises the carbon atoms which carry the groups C(:X)NH and NHSO₂R₂ is a benzene, naphthalene, (un)saturated 3-7 membered carbocycle, etc.; R₁ = (un)substituted aryl, heterocyclyl, C1-18 alkyl; R₂ = (un)substituted aryl, heterocyclyl, C1-10 alkyl, etc.; R₃ = H, halo, CF₃, etc.; n = 0-2; X = O, NH], useful for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis, were prepared. The compds. I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. Thus, reacting 4-[[2-(4-chlorophenylsulfonyl)-4,5-dimethoxybenzoyl]amino]benzenesulfonyl fluoride (preparation given) with thiomorpholine afforded 65% II which showed 34.8-fold stimulation ([cGMP]test substance/[cGMP]control) at 50 μM.

IT 254877-67-3P 254878-41-6P 254878-45-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of sulfur substituted sulfonylaminocarboxylic acid N-arylamides

as modulators of cyclic guanosine monophosphate (cGMP) production)

IT 254876-98-7P 254876-99-8P 254877-02-6P
 254877-03-7P 254877-04-8P 254877-08-2P
 254877-09-3P 254877-10-6P 254877-11-7P
 254877-12-8P 254877-13-9P 254877-14-0P
 254877-15-1P 254877-16-2P 254877-17-3P
 254877-19-5P 254877-20-8P 254877-21-9P
 254877-22-0P 254877-24-2P 254877-25-3P
 254877-28-6P 254877-29-7P 254877-30-0P
 254877-32-2P 254877-34-4P 254877-35-5P
 254877-36-6P 254877-37-7P 254877-38-8P
 254877-39-9P 254877-40-2P 254877-41-3P
 254877-42-4P 254877-43-5P 254877-44-6P
 254877-45-7P 254877-46-8P 254877-47-9P
 254877-48-0P 254877-49-1P 254877-50-4P
 254877-51-5P 254877-52-6P 254877-62-8P
 254877-63-9P 254877-64-0P 254877-65-1P
 254877-66-2P 254877-68-4P 254877-69-5P
 254877-70-8P 254877-71-9P 254877-72-0P
 254877-74-2P 254877-76-4P 254877-77-5P
 254877-78-6P 254877-79-7P 254877-80-0P
 254877-81-1P 254877-82-2P 254877-83-3P

254877-84-4P 254877-85-5P 254877-86-6P
 254877-87-7P 254877-88-8P 254877-89-9P
 254877-90-2P 254877-91-3P 254877-92-4P
 254877-93-5P 254877-95-7P 254877-96-8P
 254877-97-9P 254877-98-0P 254877-99-1P
 254878-00-7P 254878-01-8P 254878-02-9P
 254878-03-0P 254878-04-1P 254878-05-2P
 254878-06-3P 254878-07-4P 254878-08-5P
 254878-09-6P 254878-10-9P 254878-11-0P
 254878-12-1P 254878-13-2P 254878-15-4P
 254878-16-5P 254878-17-6P 254878-18-7P
 254878-20-1P 254878-21-2P 254878-22-3P
 254878-23-4P 254878-24-5P 254878-36-9P
 254878-37-0P 254878-39-2P 254878-47-2P
 254878-48-3P 254878-69-8P 254975-94-5P
 254975-96-7P 254975-97-8P 254975-98-9P
 254976-01-7P 254976-03-9P 254976-04-0P
 254976-05-1P 254976-06-2P 254976-07-3P
 254976-08-4P 254976-09-5P 254976-10-8P
 254976-11-9P 254976-12-0P 254976-13-1P
 254976-14-2P 254976-15-3P 254976-16-4P
 254976-17-5P 254976-18-6P 254976-19-7P
 254976-20-0P 254976-21-1P 254976-22-2P
 254976-23-3P 254976-24-4P 254976-25-5P
 254976-26-6P 254976-27-7P 254976-28-8P
 254976-29-9P 254976-30-2P 254976-31-3P
 254976-32-4P 254976-33-5P 254976-34-6P
 254976-35-7P 254976-36-8P 254976-37-9P
 254976-38-0P 254976-39-1P 254976-40-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfur substituted sulfonylaminocarboxylic acid N-arylamides

as modulators of cyclic guanosine monophosphate (cGMP) production)

IT 254878-46-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of sulfur substituted sulfonylaminocarboxylic acid N-arylamides

as modulators of cyclic guanosine monophosphate (cGMP) production)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:33514 CAPLUS Full-text

DOCUMENT NUMBER: 132:88199

TITLE: Sulphonylamino aryl amides as guanylate cyclase activators for therapeutic use

INVENTOR(S): **Schindler, Ursula**; Schoenafinger, Karl; **Strobel, Hartmut**

PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany
 SOURCE: Ger. Offen., 24 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

DE 19830431	A1	20000113	DE 1998-19830431	19980708
CA 2336702	A1	20000120	CA 1999-2336702	19990625
WO 2000002850	A2	20000120	WO 1999-EP4427	19990625
WO 2000002850	A3	20000413		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9951553	A	20000201	AU 1999-51553	19990625
BR 9911942	A	20010327	BR 1999-11942	19990625
EP 1095015	A2	20010502	EP 1999-936460	19990625
EP 1095015	B1	20050601		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002520308	T	20020709	JP 2000-559081	19990625
AT 296800	T	20050615	AT 1999-936460	19990625
PT 1095015	T	20050930	PT 1999-936460	19990625
ES 2242407	T3	20051101	ES 1999-936460	19990625
US 6548547	B1	20030415	US 2001-743199	20010308
US 2003171352	A1	20030911	US 2003-349907	20030124
US 6809089	B2	20041026		
US 2005080073	A1	20050414	US 2004-957980	20041005

PRIORITY APPLN. INFO.:

DE 1998-19830431	A	19980708
WO 1999-EP4427	W	19990625
US 2001-743199	A1	20010308
US 2003-349907	A1	20030124

OTHER SOURCE(S): MARPAT 132:88199

GI For diagram(s), see printed CA Issue.

AB Compds. I [A1 = (substituted) Ph, naphthyl, or heteroaryl; A2 = ring (benzene, naphthalene, (un)saturated 3-7-membered carbocyclic, (un)saturated or aromatic monocyclic 5-7-membered heterocyclic, (un)saturated or aromatic bicyclic 8-10-membered heterocyclic); R2 = C1-10 alkyl, aryl, etc.; R3 = H, Halo, CF₃, OH, etc.], e.g. 2-(4-chlorophenylsulfonylamino)-N-(3-trifluoromethylphenyl)benzamide, are disclosed for prophylaxis and treatment of disease, e.g. cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thrombosis and atherosclerosis. The compds. of the invention can modulate cGMP production and are suitable generally for the treatment and prophylaxis of disease states associated with impaired cGMP metabolism. The invention also discloses preparation of medicaments, novel compds. of formula I, pharmaceutical compns., and preparation methods.

L33 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:31524 CAPLUS Full-text

DOCUMENT NUMBER: 132:93102

TITLE: Preparation of arylsulfonylaminoarylamides as guanylate cyclase activators.

INVENTOR(S): **Schindler, Ursula**; Schoenafinger, Karl; **Strobel, Hartmut**

PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany

SOURCE: Ger. Offen., 24 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19830430	A1	20000113	DE 1998-19830430	19980708
CA 2336807	A1	20000120	CA 1999-2336807	19990625
WO 2000002851	A1	20000120	WO 1999-EP4426	19990625
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9946160	A	20000201	AU 1999-46160	19990625
AU 761983	B2	20030612		
BR 9911914	A	20010327	BR 1999-11914	19990625
EP 1095016	A1	20010502	EP 1999-929318	19990625
EP 1095016	B1	20051109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
TR 200100147	T2	20010521	TR 2001-200100147	19990625
HU 200104905	A2	20020629	HU 2001-4905	19990625
JP 2002520309	T	20020709	JP 2000-559082	19990625
JP 3786579	B2	20060614		
RU 2234497	C2	20040820	RU 2001-103645	19990625
AT 309206	T	20051115	AT 1999-929318	19990625
EP 1614678	A2	20060111	EP 2005-21577	19990625
EP 1614678	A3	20060322		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
ES 2251200	T3	20060416	ES 1999-929318	19990625
TW 234558	B	20050621	TW 1999-88111401	19990706
US 6335334	B1	20020101	US 1999-349933	19990708
ZA 2000007486	A	20020104	ZA 2000-7486	20001214
NO 2001000013	A	20010301	NO 2001-13	20010102
IN 2001CN00029	A	20050304	IN 2001-CN29	20010108
US 2002061887	A1	20020523	US 2001-994730	20011128
US 6881735	B2	20050419		
US 2004186145	A1	20040923	US 2004-816143	20040402
JP 2006143737	A	20060608	JP 2005-343295	20051129
PRIORITY APPLN. INFO.:				
			DE 1998-19830430	A 19980708
			DE 1999-19903126	A 19990127
			EP 1999-929318	A3 19990625
			JP 2000-559082	A3 19990625
			WO 1999-EP4426	W 19990625
			US 1999-349933	A3 19990708
			US 2001-994730	A3 20011128

OTHER SOURCE(S): MARPAT 132:93102
GI



AB Title compds. [I; A1 = (substituted) phenylene, naphthylene, heteroarylene; A2 = atoms to form Ph, naphthyl, carbocyclyl, heterocyclyl rings; R1 = (substituted) aryl, heterocyclyl, alkyl; R2 = R1, amino; R3 = ≥ 1 of H, halo, CF₃, OH, alkoxy, alkoxyalkoxy, aryloxy, NO₂, cyano, amino, CO₂H, etc.; X = O, NH, etc.; n = 0-2], were prepared. Thus, 4-[[2-(4-chlorophenylsulfonylamino)-4,5-dimethoxybenzoyl]amino]benzenesulfonyl fluoride was heated in thiomorpholine at 90° for 30 min. to give 65% 2-(4-chlorophenylsulfonylamino)-4,5-dimethoxy-N-[4-(thiomorpholin-4-sulfonyl)phenyl]benzamide. The latter at 50 μ M gave 34.8-fold stimulation of soluble guanylate cyclase.

IT 254876-98-7P 254876-99-8P 254877-00-4P
254877-02-6P 254877-03-7P 254877-04-8P
254877-08-2P 254877-09-3P 254877-10-6P
254877-11-7P 254877-12-8P 254877-13-9P
254877-14-0P 254877-15-1P 254877-16-2P
254877-17-3P 254877-19-5P 254877-20-8P
254877-21-9P 254877-22-0P 254877-24-2P
254877-25-3P 254877-26-4P 254877-28-6P
254877-29-7P 254877-30-0P 254877-31-1P
254877-32-2P 254877-33-3P 254877-34-4P
254877-35-5P 254877-36-6P 254877-37-7P
254877-38-8P 254877-39-9P 254877-40-2P
254877-41-3P 254877-42-4P 254877-43-5P
254877-44-6P 254877-45-7P 254877-46-8P
254877-47-9P 254877-48-0P 254877-49-1P
254877-50-4P 254877-51-5P 254877-52-6P
254877-53-7P 254877-62-8P 254877-63-9P
254877-64-0P 254877-65-1P 254877-66-2P
254877-67-3P 254877-68-4P 254877-69-5P
254877-70-8P 254877-71-9P 254877-72-0P
254877-74-2P 254877-76-4P 254877-77-5P
254877-78-6P 254877-79-7P 254877-80-0P
254877-81-1P 254877-82-2P 254877-83-3P
254877-84-4P 254877-85-5P 254877-86-6P
254877-87-7P 254877-88-8P 254877-89-9P
254877-90-2P 254877-91-3P 254877-92-4P
254877-93-5P 254877-94-6P 254877-95-7P
254877-96-8P 254877-97-9P 254877-98-0P
254877-99-1P 254878-00-7P 254878-01-8P
254878-02-9P 254878-03-0P 254878-04-1P
254878-05-2P 254878-06-3P 254878-07-4P
254878-08-5P 254878-09-6P 254878-10-9P
254878-11-0P 254878-12-1P 254878-13-2P
254878-15-4P 254878-16-5P 254878-17-6P
254878-18-7P 254878-19-8P 254878-20-1P
254878-21-2P 254878-22-3P 254878-23-4P
254878-24-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylsulfonylaminoarylamides as guanylate cyclase activators)

IT 254878-46-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of arylsulfonylaminoarylamides as guanylate cyclase

activators)

IT 254878-36-9P 254878-37-0P 254878-39-2P
254878-41-6P 254878-45-0P 254878-47-2P
254878-48-3P 254878-69-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylsulfonylaminoarylamides as guanylate cyclase activators)

L33 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:789225 CAPLUS Full-text

DOCUMENT NUMBER: 132:73434

TITLE: Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase

AUTHOR(S): Wohlfart, Paulus; Malinski, Tadeusz; Ruetten, Hartmut; **Schindler, Ursula**; Linz, Wolfgang; Schoenafinger, Karl; **Strobel, Hartmut**; Wiemer, Gabriele

CORPORATE SOURCE: Hoechst Marion Roussel, Frankfurt, Germany

SOURCE: British Journal of Pharmacology (1999), 128(6), 1316-1322

CODEN: BJPCBM; ISSN: 0007-1188

PUBLISHER: Stockton Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In this study we examined the endothelium-dependent effect of YC-1-a benzyl indazole derivative which directly activates soluble guanylyl cyclase (sGC) - on vascular relaxation and nitric oxide (NO) and guanosine-3',5'-cyclic monophosphate (cGMP) in endothelial cells. In precontracted rat aortic rings with intact endothelium, YC-1 produced a concentration-dependent relaxation. However, the concentration response curve was shifted rightward to higher concns. of YC-1, when (i) the aortas were pre-treated with L-NG-nitroarginine methylester (L-NAME) or (ii) the endothelium was removed. Incubation of bovine aortic endothelial cells (BAEC) with YC-1 produced a concentration-dependent NO synthesis and release as assessed using a porphyrinic microsensor. Pre-incubating cells with L-NAME or with 8-bromo-cGMP decreased this effect indicating that the YC-1 stimulation of NO synthesis is due to an activation of nitric oxide synthase, but not to an elevation of cGMP. No direct effect of YC-1 on recombinant endothelial constitutive NO synthase activity was observed. The YC-1 stimulated NO release was reduced by 90%, when extracellular free calcium was diminished. In human umbilical vein endothelial cells (HUVEC), YC-1 stimulated intracellular cGMP production in a concentration- and time-dependent manner. Stimulation of cGMP was greater with a maximum concentration of YC-1 compared to calcium ionophore A23187. Similar effects were observed in BAEC and rat microvascular coronary endothelial cells (RMCEC). When HUVEC and RMCEC were pre-treated with L-NG-nitroarginine (L-NOARG), the maximum YC-1 stimulated cGMP increase was reduced by $\geq 50\%$. These results indicate, that beside being a direct activator of sGC, YC-1 stimulates a NO-synthesis and release in endothelial cells which is independent of elevation of cGMP but strictly dependent on extracellular calcium. The underlying mechanism needs to be determined further.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:549254 CAPLUS Full-text

DOCUMENT NUMBER: 131:170265

TITLE: Substituted isoindolones and their use as cyclic GMP modulators in pharmaceuticals

INVENTOR(S): **Schindler, Ursula**; **Schonafinger, Karl**; **Strobel, Hartmut**; Groehn, Viola

PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9942444	A1	19990826	WO 1999-EP931	19990212
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19807423	A1	19990826	DE 1998-19807423	19980221
CA 2320822	A1	19990826	CA 1999-2320822	19990212
AU 9927253	A	19990906	AU 1999-27253	19990212
EP 1064262	A1	20010103	EP 1999-907548	19990212
EP 1064262	B1	20030212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002503721	T	20020205	JP 2000-532396	19990212
AT 232516	T	20030215	AT 1999-907548	19990212
PT 1064262	T	20030731	PT 1999-907548	19990212
ES 2190644	T3	20030801	ES 1999-907548	19990212
US 6344468	B1	20020205	US 2000-622691	20001006
PRIORITY APPLN. INFO.:			DE 1998-19807423	A 19980221
			WO 1999-EP931	W 19990212

OTHER SOURCE(S): MARPAT 131:170265

AB The invention relates to substituted isoindolone derivs. which represent active substances in pharmaceuticals for the therapy and prophylaxis of diseases, e.g. cardiovascular diseases such a hypertension, angina pectoris, heart failures, thrombosis or atherosclerosis. The indolones are capable of modulating endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of pathol. states associated with disorders of the cGMP metabolism. The invention also relates to a method for the production of the title compds., their use in the therapy and prophylaxis of the above-mentioned pathol. states and in the production of pharmaceuticals for such states. Approx. 35 title compds. were prepared either by cyclization of an amine with o-benzoylbenzoyl chloride or by Grignard reaction of a halide with a phthalimide. E.g., 2-(2-fluorophenyl)ethylamine cyclized with o-benzoylbenzoyl chloride to give 2-[2-(2-fluorophenyl)ethyl]-3-hydroxy-3-phenyl-2,3-dihydro-1-isoindolone and Grignard reaction of 4-fluorophenylmagnesium bromide with N-[2-(3-methoxyphenyl)ethyl]phthalimi de gave 3-(4-fluorophenyl)-3-hydroxy-2-[2-(3-methoxyphenyl)ethyl]-2,3-dihydro-1-isoindolone.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:409556 CAPLUS Full-text
DOCUMENT NUMBER: 131:58845
TITLE: Substituted 2-aryl-4-amino-quinazolines
INVENTOR(S): **Schindler, Ursula**; Schindler, Peter;
Schoenafinger, Karl; **Strobel, Hartmut**
PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany
SOURCE: Ger. Offen., 22 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent

LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19756388	A1	19990624	DE 1997-19756388	19971218
CA 2315205	A1	19990701	CA 1998-2315205	19981211
WO 9932460	A1	19990701	WO 1998-EP8097	19981211
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9922708	A	19990712	AU 1999-22708	19981211
EP 1040101	A1	20001004	EP 1998-966301	19981211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2001526273	T	20011218	JP 2000-525397	19981211
US 6613772	B1	20030902	US 2000-581763	20000616
PRIORITY APPLN. INFO.:			DE 1997-19756388	A 19971218
			WO 1998-EP8097	W 19981211

OTHER SOURCE(S): MARPAT 131:58845

AB Substituted 2-aryl-4-amino-quinazolines and their use as cardiovascular agents for treatment circulatory disease, blood pressure, angina, pectoris, heart insufficiency, thrombosis or atherosclerosis and to modulate the production of cGMP. Thus, 2-(4-chlorophenyl)-4-N-benzylpiperzino- 6,7,8-trimethoxyquinazoline was prepared in a multistep process from Me 2-amino-3,4,5-trimethoxybenzoate and 4-chlorobenzoyl chloride and subsequently with N-benzylpiperazine.

L33 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:238555 CAPLUS Full-text

DOCUMENT NUMBER: 130:267435

TITLE: Preparation of pyrazolo[3,4-b]pyridines as cardiovascular agents.

INVENTOR(S): **Schindler, Ursula**; Schoenafinger, Karl;
Strobel, Hartmut

PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany

SOURCE: Ger. Offen., 16 pp.

CODEN: GWXXBX


DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19744027	A1	19990408	DE 1997-19744027	19971006
PRIORITY APPLN. INFO.:			DE 1997-19744027	19971006
OTHER SOURCE(S):		MARPAT 130:267435		
GI				




AB Title compds. [I; X = O, S, NH, NMe; R1, R1a = H, halo, COR10, (substituted) (unsatd.) alkyl; R2 = alkyl, (substituted) phenylalkyl; R3, R5 = H, OH, alkoxy, alkyl, (substituted) Ph, PhCH2O; R4 = H, alkyl, (substituted) Ph, phenylalkyl; R10 = H, alkyl, (substituted) Ph], were prepared Thus, 1-benzyl-3-(5-formyl-2-furyl)-4,6-dimethylpyrazolo[3,4- b]pyridine (preparation given) was stirred with NaBH4 in EtOH to give 1-benzyl-3-(5-hydroxymethyl-2-furyl)-4,6-dimethylpyrazolo[3,4-b]pyridine. The latter at 50 μ M gave a 3-fold stimulation of soluble guanylate cyclase activity.

L33 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:238554 CAPLUS Full-text
 DOCUMENT NUMBER: 130:267427
 TITLE: Preparation of heterocyclylpyrazoles as cardiovascular agents.
 INVENTOR(S): **Schindler, Ursula**; Schoenafinger, Karl;
Strobel, Hartmut
 PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany
 SOURCE: Ger. Offen., 28 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19744026	A1	19990408	DE 1997-19744026	19971006
IN 1998MA02166	A	20050304	IN 1998-MA2166	19980925
EP 908456	A1	19990414	EP 1998-118494	19980930
EP 908456	B1	20031217		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 256680	T	20040115	AT 1998-118494	19980930
EP 1418176	A1	20040512	EP 2003-28260	19980930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI, CY				
PT 908456	T	20040531	PT 1998-118494	19980930
ES 2212192	T3	20040716	ES 1998-118494	19980930
CA 2249542	A1	19990406	CA 1998-2249542	19981005
AU 9887912	A	19990422	AU 1998-87912	19981005
AU 749595	B2	20020627		
JP 11302277	A	19991102	JP 1998-282345	19981005
HU 9802224	A1	19991228	HU 1998-2224	19981005
US 6162819	A	20001219	US 1998-166283	19981005
CN 1214339	A	19990421	CN 1998-120881	19981006
BR 9803880	A	20000502	BR 1998-3880	19981006

US 2003105336	A1	20030605	US 2002-252825	20020924
US 6897232	B2	20050524		
US 2005176799	A1	20050811	US 2005-104556	20050413
PRIORITY APPLN. INFO.:			DE 1997-19744026	A 19971006
			EP 1998-118494	A3 19980930
			US 1998-166283	A3 19981005
			US 2000-702669	B1 20001101
			US 2002-252825	A3 20020924
OTHER SOURCE(S):	MARPAT 130:267427			
GI				






AB Title compds. [I; X = O, S, NH, NMe; R¹, R^{1a} = H, halo, OR⁶, NR⁷R⁸, CO²R⁹, COR¹⁰, cyano, NO₂, (substituted) alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclalkyl, etc.; R², R³ = H (substituted) alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclalkyl; R²R³ = atoms to form a (substituted) (unsatd.) 5-7 membered ring; R⁴ = H, (substituted) alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclalkyl; n = 0-2; R⁶-R⁸ = H, (substituted) alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclalkyl, etc.; R⁹, R¹⁰ = H, (substituted) alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclalkyl], were prepared Thus, 5-(2-fluorobenzoyl)furan-2-carboxylic acid was refluxed with PhCH₂NHNH₂ in HOAc to to give the benzylhydrazone, which was refluxed with KOCMe₃ in DMF to give 1-benzyl-3-(5-carboxy-2-furyl)indazole potassium salt. This was refluxed through a water separator with EtOH and H₂SO₄ in PhMe to give 1-benzyl-3-(5-ethoxycarbonyl-2-furyl)indazole, which was refluxed with HOCH₂CH₂OH to give 1-benzyl-3-[5-[(2-hydroxyethoxy)carbonyl]-2-furyl]indazole. The latter at 100 μM stimulated a 5.5-fold increase in soluble guanylate cyclase activity.

L33 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:509337 CAPLUS Full-text
 DOCUMENT NUMBER: 125:168036
 TITLE: 1,3-Thiazepine-2-amines and their use as inhibitors of the nitric oxide synthase
 INVENTOR(S): **Strobel, Hartmut**; Bohn, Helmut; Klingler, Otmar; **Schindler, Ursula**; Schoenafinger, Karl; Zoller, Gerhard
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Eur. Pat. Appl., 24 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 718294	A1	19960626	EP 1995-118404	19951123
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
DE 4444930	A1	19960627	DE 1994-4444930	19941216
JP 08231521	A	19960910	JP 1995-325903	19951214
CA 2165386	A1	19960617	CA 1995-2165386	19951215
PRIORITY APPLN. INFO.:			DE 1994-4444930	A 19941216
OTHER SOURCE(S):	MARPAT 125:168036			

GI



AB The 1,3-thiazepin-2-amines I [W, X, Y, Z = (un)substituted methine] were disclosed and their uses were claimed for the treatment of diseases related to increased nitrogen monoxide levels. Example compds. are 4,5,6,7-tetrahydro-1,3-thiazepin-2-amine hydrochloride (II) and 1,5-dihydro-2,4-benzothiazepin-3-amine hydrochloride (III). The use of 1,3-thiazepine-2-amines as inhibitors of nitrogen oxide synthase was claimed. These compds. are useful for the treatment or prophylaxis of a pathol. decrease in blood pressure related to septic shock or cancer treatment with cytokines. These compds. were also claimed for the treatment or prophylaxis of inflammatory diseases, such as ulcerative colitis, and for the treatment or prophylaxis of damage related to infarction and tissue reperfusion and for the treatment of graft-vs.-host disease. The use of these 1,3-thiazepin-2-amines for the treatment of nervous system diseases, such as Alzheimer, migraines, and epilepsy was also claimed.

L33 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:417899 CAPLUS Full-text
 DOCUMENT NUMBER: 125:67775
 TITLE: 2-Amino-1,3-thiazines as nitric oxide synthase inhibitors
 INVENTOR(S): **Strobel, Hartmut**; Bohn, Helmut; Klemm, Peter; Klingler, Otmar; **Schindler, Ursula**; Schoenafinger, Karl; Zoller, Gerhard
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Eur. Pat. Appl., 21 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 713704	A1	19960529	EP 1995-117500	19951107
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
DE 4442116	A1	19960530	DE 1994-4442116	19941125
JP 08239369	A	19960917	JP 1995-304474	19951122
CA 2163724	A1	19960526	CA 1995-2163724	19951124

PRIORITY APPLN. INFO.:

DE 1994-4442116

A 19941125

OTHER SOURCE(S):

MARPAT 125:67775

AB Ring-substituted 2-amino-1,3-thiazines are NO synthase inhibitors useful for treatment of diseases characterized by elevated NO levels, e.g. hypotension, rheumatoid arthritis, ulcerative colitis, diabetes mellitus, and transplant rejection. Thus, 2-amino-6-phenyl-5,6-dihydro-4H-1,3- thiazine-HCl was prepared by refluxing 3-amino-1-phenyl-1-propanol with tert-Bu isothiocyanate. Tablets were prepared containing active ingredient 40, lactose 600, corn starch 300, soluble starch 20, and Mg stearate 40 mg.

=> file registry

FILE 'REGISTRY' ENTERED AT 14:07:44 ON 30 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 29 MAR 2007 HIGHEST RN 928707-03-3
DICTIONARY FILE UPDATES: 29 MAR 2007 HIGHEST RN 928707-03-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> file caplus

FILE 'CAPLUS' ENTERED AT 14:07:46 ON 30 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 30 Mar 2007 VOL 146 ISS 15
FILE LAST UPDATED: 29 Mar 2007 (20070329/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:



<http://www.cas.org/infopolicy.html>
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d stat que L21
L3 STR



G1 [01],[02]

Structure attributes must be viewed using STN Express query preparation:
Uploading L3.str



chain nodes :
16 20 21
ring nodes :
1 2 3 4 5 6 15
ring/chain nodes :
7 8 9 13 14 17
chain bonds :
4-7 5-20 15-16 20-21
ring/chain bonds :
7-13 7-14 14-17 15-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :
4-7 5-20 7-13 7-14 14-17 15-16 15-17 20-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 13:CLASS
14:CLASS 15:Atom 16:CLASS 17:CLASS 20:CLASS 21:CLASS

L6 512 SEA FILE=REGISTRY SSS FUL L3
L19 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZANILIDE, 3,5,5'-TRICHLOR
O-2'-((P-CHLOROPHENYL)THIO)-2-METHANESULFONAMIDO-"/CN
L20 511 SEA FILE=REGISTRY ABB=ON PLU=ON L6 NOT L19
L21 55 SEA FILE=CAPLUS ABB=ON PLU=ON L20

=> s L21 not L33
L35 51 L21 NOT L33

=> d ibib abs hitstr L35 1-51

L35 ANSWER 1 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:122679 CAPLUS Full-text
DOCUMENT NUMBER: 146:287556
TITLE: Significant pharmacokinetic and pharmacodynamic
interaction of warfarin with the NO-independent sGC
activator HMR1766
AUTHOR(S): Oberwittler, Heike; Hirschfeld-Warneken, Andreas;
Wesch, Roland; Willerich, Hans; Teichert, Lenore;
Lehr, Karl-Heinz; Ding, Reinhard; Haefeli, Walter
Emil; Mikus, Gerd
CORPORATE SOURCE: University of Heidelberg, Heidelberg, Germany
SOURCE: Journal of Clinical Pharmacology (2007), 47(1), 70-77
CODEN: JCPCBR; ISSN: 0091-2700
PUBLISHER: Sage Publications
DOCUMENT TYPE: Journal
LANGUAGE: English


AB HMR1766 is a new nitric oxide (NO)-independent activator of soluble guanylyl cyclase (sGC) in development for the treatment of cardiovascular diseases and chronic heart failure. A significant fraction of patients to be treated with HMR1766 is expected to be maintained on warfarin. Because HMR1766 is an inhibitor and warfarin a substrate of CYP2C9, the authors studied whether warfarin pharmacokinetics and pharmacodynamics are influenced by HMR1766. Eighteen healthy males were to receive a single oral dose of 20 mg warfarin each under steady-state conditions of HMR1766 or placebo. Plasma concns. of HMR1766, (R)- and (S)-warfarin, and its 7-hydroxy-metabolites were determined using high-performance liquid chromatog. and prothrombin time, and the international standardized ratio was determined by the nephelometric method. (S)-Warfarin AUC_{inf} and t_{1/2} were 106 471 h·µg/L and 82.92 h vs. 33 148 h·µg/L under HMR1766 and 31.72 h under placebo, and the maximum decrease in prothrombin time values after warfarin dosing was 58.75% vs. 39.94%. These data demonstrate a CYP2C9-mediated pharmacokinetic interaction with pharmacodynamic, clin. relevant consequences, which might require warfarin dose adjustment.

IT 254877-67-3, HMR1766

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(CYP2C9-mediated pharmacokinetic interaction between HMR1766 and
warfarin with pharmacodynamic consequences)

RN 254877-67-3 CAPLUS

CN Benzamide, 5-chloro-2-[[[5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-
morpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:87236 CAPLUS Full-text

DOCUMENT NUMBER: 146:156240

TITLE: Novel use of activators and stimulators of soluble
guanylate cyclase for the prevention or treatment of
renal disorders

INVENTOR(S): Krahn, Thomas; Stasch, Johannes-Peter; Weimann,
Gerrit; Thielemann, Wolfgang; Rinke, Matthias

PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany

SOURCE: PCT Int. Appl., 17pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2007009607	A1	20070125	WO 2006-EP6601	20060706
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: EP 2005-15522 A 20050718

AB The present invention relates generally to a use for the production of a
medicament for the treatment of renal failure or renal hypertension and, more
particularly, to a production of a medicament for improving the recovery from

acute renal failure or renal hypertension by treatment with activators of soluble guanylate cyclase or stimulators of guanylate cyclase. Efficacy of guanylate cyclase activators and stimulators in rats with impaired kidneys is shown.


IT 254976-06-2 918475-55-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(novel use of activators and stimulators of soluble guanylate cyclase for prevention or treatment of renal disorders)

RN 254976-06-2 CAPLUS


CN Benzamide, 5-chloro-2-[[5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 918475-55-5 CAPLUS

CN Benzamide, 5-chloro-2-[[3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]-N-[4-[(2,6-dimethyl-4-morpholinyl)sulfonyl]phenyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na

REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 3 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:86282 CAPLUS Full-text

DOCUMENT NUMBER: 146:156239

TITLE: Use of activators of soluble guanylate cyclase for the treatment of reperfusion injury
 INVENTOR(S): Krahn, Thomas; Stasch, Johannes Peter; Weimann, Gerrit; Thielemann, Wolfgang
 PATENT ASSIGNEE(S): Bayer Healthcare AG, Germany
 SOURCE: Ger. Offen., 8pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102005031576	A1	20070125	DE 2005-102005031576	20050706
WO 2007025595	A1	20070308	WO 2006-EP6600	20060706

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: DE 2005-102005031576A 20050706

AB The invention discloses the use of compds. which are activators of soluble guanylate cyclase for production of pharmaceutical products/drugs for prophylaxis and/or treatment of reperfusion damage.


IT 254976-06-2 918475-55-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(soluble guanylate cyclase activators for treatment of reperfusion injury)

RN 254976-06-2 CAPLUS


CN Benzamide, 5-chloro-2-[[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 918475-55-5 CAPLUS

CN Benzamide, 5-chloro-2-[[[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]-N-[4-[(2,6-dimethyl-4-morpholinyl)sulfonyl]phenyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na

L35 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:61517 CAPLUS Full-text
 DOCUMENT NUMBER: 146:135561
 TITLE: Use of activators of soluble guanylate cyclase for
 treatment of Raynaud phenomenon
 PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
 SOURCE: Ger. Offen., 7pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102005047945	A1	20070118	DE 2005-102005047945	20051006
WO 2007009589	A2	20070125	WO 2006-EP6501	20060704
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: DE 2005-102005033370IA 20050716
 DE 2005-102005047945A 20051006

GI

AB The invention discloses the use of compds. I-VI for production of a drug for treatment of primary and secondary Raynaud phenomenon.


IT 254976-06-2 254976-06-2D, hydrates 918475-55-5
918475-55-5D, hydrates

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(soluble guanylate cyclase activators for treatment of Raynaud phenomenon)

RN 254976-06-2 CAPLUS


CN Benzamide, 5-chloro-2-[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 254976-06-2 CAPLUS


CN Benzamide, 5-chloro-2-[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 918475-55-5 CAPLUS

CN Benzamide, 5-chloro-2-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]-N-[4-[(2,6-dimethyl-4-morpholinyl)sulfonyl]phenyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 918475-55-5 CAPLUS
 CN Benzamide, 5-chloro-2-[[[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]-N-[4-[(2,6-dimethyl-4-morpholinyl)sulfonyl]phenyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na


L35 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:37769 CAPLUS Full-text
 DOCUMENT NUMBER: 146:115076
 TITLE: Use of activators of soluble guanylate cyclase for promoting the healing of wounds
 INVENTOR(S): Krahn, Thomas; Stasch, Johannes-Peter; Weimann, Gerrit; Thielemann, Wolfgang; Stelte-Ludwig, Beatrix
 PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
 SOURCE: PCT Int. Appl., 15pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007003435	A2	20070111	WO 2006-EP6598	20060706
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102005031575	A1	20070111	DE 2005-102005031575	20050706
PRIORITY APPLN. INFO.:			DE 2005-102005031575A	20050706
AB	The invention discloses the use of soluble guanylate cyclase activators for production of a medicament for promoting wound healing.			
IT	254976-06-2 918475-55-5			
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(soluble guanylate cyclase activators for promoting wound healing)			
RN	254976-06-2 CAPLUS			
CN	Benzamide, 5-chloro-2-[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]-, monosodium salt (9CI) (CA INDEX NAME)			



● Na

RN 918475-55-5 CAPLUS
 CN Benzamide, 5-chloro-2-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]-N-[4-[(2,6-dimethyl-4-morpholinyl)sulfonyl]phenyl]-, sodium salt (1:1) (CA INDEX NAME)



L35 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:1185581 CAPLUS Full-text
 DOCUMENT NUMBER: 146:55135

TITLE: Soluble Guanylyl Cyclase Activation With HMR1766 Attenuates Platelet Activation in Diabetic Rats
 AUTHOR(S): Schaefer, Andreas; Flierl, Ulrike; Kobsar, Anna; Eigenthaler, Martin; Ertl, Georg; Bauersachs, Johann
 CORPORATE SOURCE: Medizinische Klinik und Poliklinik I, Universitaetsklinikum Wuerzburg, Julius-Maximilians-Universitaet Wuerzburg, Germany
 SOURCE: Arteriosclerosis, Thrombosis, and Vascular Biology (2006), 26(12), 2813-2818
 CODEN: ATVBFA; ISSN: 1079-5642
 PUBLISHER: Lippincott Williams & Wilkins
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB Platelet activation significantly contributes to cardiovascular morbidity and mortality in diabetes. An association between impaired NO-mediated platelet inhibition and platelet activation has recently been demonstrated in exptl. diabetes. Guanylyl cyclase activation enhances the reduced signaling via the NO/cGMP pathway. The authors investigated whether chronic guanylyl cyclase activation would beneficially modulate platelet activation in exptl. diabetes mellitus. Diabetes was induced by streptozotocin-injection in male Wistar rats. After 2 wk, treatment with either placebo or the guanylyl cyclase activator HMR1766 (10 mg/kg twice daily by gavage) was initiated. Two weeks later, in vivo platelet activation and in vitro platelet reactivity were assessed. Chronic treatment with HMR1766 enhanced NO/cGMP-mediated signaling in platelets from diabetic rats determined by in vivo phosphorylation of platelet vasodilator-stimulated phosphoprotein (VASP) at Ser157 and Ser239. In parallel, platelet-binding of fibrinogen, surface-expression of P-selectin, appearance of platelet-derived microparticles, and platelet-aggregates with other blood cells were significantly reduced by chronic treatment with HMR1766. Chronic activation of soluble guanylyl cyclase in diabetic rats improved markers of platelet activation and is a rationale approach for prevention of adverse cardiovascular events in diabetes.

IT 254877-67-3, HMR1766

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats)

RN 254877-67-3 CAPLUS
 CN Benzamide, 5-chloro-2-[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:1012671 CAPLUS Full-text
 DOCUMENT NUMBER: 145:377381
 TITLE: Preparation of quinazolines as modulators of ion channels
 INVENTOR(S): Gonzalez, Jesus E.; Wilson, Dean M.; Termin, Andreas P.; Grootenhuys, Peter D. J.; Zhang, Yulian; Petzoldt, Benjamin J.; Fanning, Lev Tyler Dewey; Neubert, Timothy D.; Tung, Roger D.; Martinborough, Esther; Zimmerman, Nicole
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 351pp., Cont.-in-part of U.S. Ser. No. 792,688.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE.
US 2006217377	A1	20060928	US 2004-935008	20040902
US 2004248890	A1	20041209	US 2004-792688	20040303
PRIORITY APPLN. INFO.:			US 2003-451458P	P 20030303
			US 2003-463797P	P 20030418
			US 2004-792688	A2 20040303

OTHER SOURCE(S): MARPAT 145:377381
 GI



AB The title compds. [I; NR1R2 = (un)substituted 3-12 membered monocyclic or bicyclic (un)saturated ring having 0-3 heteroatoms selected from N, S or O; ring A = (un)substituted 5-7 membered aryl, 8-10 membered bicyclic aryl having 0-3 heteroatoms selected from N, S or O, etc.; x = 0-4; R3 = QR (wherein Q = a bond, alkylidene wherein up to two non-adjacent methylene units are optionally replaced by S, O, CS, etc.; R = halo, NO2, CN, etc.); with provisos], useful as inhibitors of voltage-gated sodium channels and calcium channels, were prepared. Thus, reacting 2-(4-chloro-7-methylquinazolin-2-yl)phenol with 4-aminopiperidine in the presence of Et3N in CH2Cl2 afforded 89% II. Representative compds. I were found to possess desired N-type calcium channel modulation activity and selectivity (no specific data given). Also, representative compds. I were found to possess desired voltage gated sodium channel activity and selectivity (no specific data given). The invention also provides pharmaceutically acceptable compns. comprising the compds. I and methods of using the compns. in the treatment of various disorders.


IT 757991-61-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolines as modulators of ion channels for treating pain associated with various diseases)

RN 757991-61-0 CAPLUS

CN Methanesulfonamide, N-[2-[4-[4-(butylsulfonyl)-1-piperazinyl]-7-methyl-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)



L35 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:91781 CAPLUS Full-text

DOCUMENT NUMBER: 144:429404

TITLE: cGMP signaling: from bench to bedside

AUTHOR(S): Feil, Robert; Kemp-Harper, Barbara

CORPORATE SOURCE: Interfakultaeres Institut fuer Biochemie, Universitaet Tuebingen, Tuebingen, 72076, Germany

SOURCE: EMBO Reports (2006), 7(2), 149-153

CODEN: ERMEAX; ISSN: 1469-221X

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal; General Review


LANGUAGE: English

AB A review. Basic mechanisms and therapeutic potential of cGMP signaling are discussed. CGMP generators (soluble and particulate guanylyl cyclases) and cGMP effectors (cGMP-dependent protein kinases and phosphodiesterases) are described. Therapeutic potential of cGMP-elevating drugs in the treatment of cardiovascular diseases and Alzheimer's disease is also discussed,.

IT **254877-67-3**, HMR1766
 RL: BSU (Biological study, unclassified); DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (basic mechanisms and therapeutic potential of cGMP signaling)

RN 254877-67-3 CAPLUS

CN Benzamide, 5-chloro-2-[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:409351 CAPLUS Full-text
 DOCUMENT NUMBER: 142:435861
 TITLE: Novel combination for treating hypertension
 INVENTOR(S): Fox, David Nathan Abraham; Karran, Eric
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042022	A2	20050512	WO 2004-IB3444	20041020
WO 2005042022	A3	20050804		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				


PRIORITY APPLN. INFO.: GB 2003-25291 A 20031029

AB Combination comprising (a) an activator of soluble guanylate cyclase and (b) and angiotensin II receptor antagonist are useful for treating hypertension. Active ingredients (50 mg) were blended with cellulose (microcryst.), silicon dioxide, stearic acid (fumed), and the mixture was compressed to form tablets.

IT **254877-67-3**, HMR1766
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel combination for treating hypertension)

RN 254877-67-3 CAPLUS

CN Benzamide, 5-chloro-2-[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



L35 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:120761 CAPLUS Full-text

DOCUMENT NUMBER: 142:191266

TITLE: soluble guanylate cyclase activator and ACE-inhibitor for the treatment of cardiovascular or metabolic disorders

INVENTOR(S): Fox, David Nathan Abraham; Karran, Eric Howard

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 27 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011727	A1	20050210	WO 2004-IB2469	20040726
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005059660	A1	20050317	US 2004-902316	20040729
PRIORITY APPLN. INFO.:			GB 2003-18094	A 20030801
			US 2003-500748P	P 20030904

AB The invention discloses combinations comprising (a) an activator of soluble guanylate cyclase and (b) an inhibitor of angiotensin converting enzyme (ACE)

for treating a cardiovascular or metabolic disorder, in particular hypertension or diabetes.


IT 254877-67-3, HMR 1766

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(soluble guanylate cyclase activator and ACE-inhibitor for treatment of cardiovascular or metabolic disorders)

RN 254877-67-3 CAPLUS

CN Benzamide, 5-chloro-2-[[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 11 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:964830 CAPLUS Full-text

DOCUMENT NUMBER: 141:410932

TITLE: Preparation of benzo[1,2,5]thiadiazoles as CCK2 modulators for treatment of gastrointestinal disorders, pain, and other conditions

INVENTOR(S): Allison, Brett; McAtee, Laura C.; Phuong, Victor K.; Rabinowitz, Michael H.; Shankley, Nigel P.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 81 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004224983	A1	20041111	US 2004-811292	20040326
AU 2004261547	A1	20050210	AU 2004-261547	20040326
CA 2520546	A1	20050210	CA 2004-2520546	20040326
WO 2005012275	A2	20050210	WO 2004-US9589	20040326
WO 2005012275	A3	20060511		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

BR 2004008899	A	20060418	BR 2004-8899	20040326
EP 1675837	A2	20060705	EP 2004-785868	20040326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1829704	A	20060906	CN 2004-80014470	20040326
JP 2006528241	T	20061214	JP 2006-532352	20040326
NO 2005005002	A	20051214	NO 2005-5002	20051027
IN 2005KN02161	A	20061013	IN 2005-KN2161	20051031
PRIORITY APPLN. INFO.:			US 2003-458638P	P 20030328
			WO 2004-US9589	W 20040326

OTHER SOURCE(S): MARPAT 141:410932
GI




AB Title [[(2,1,3-benzothiadiazol-4-yl)sulfonyl]amino]benzamides I [wherein R1, R2 = independently H, (cyclo)alkyl, (cyclo)alkenyl, alkynyl, naphthyl, benzoylalkyl, Ph, etc.; or NR1R2 = (un)substituted 10-oxa-4-azatricyclo[5.2.1.0^{2,6}]dec-4-yl, heterocyclyl, 8-oxo-1,5,6,8-tetrahydro-2H-4H-1,5-methanopyrido[1,2-a][1,5]diazocin-3-yl; R1 = independently (cyclo)alkyl, alkenyl, Ph, furanyl, thienyl, benzyl, pyrrolyl, OH, alkoxy, SH, CN, NO₂, NH₂, halo, etc.; Rb = independently alkyl, halo; and enantiomers, diastereomers, hydrates, solvates, and pharmaceutically acceptable salts thereof] were prepared as cholecystinin 2 (CCK2) receptor modulators. For example, 4-bromo-2-aminobenzoic acid piperidine amide (3-step preparation given) was coupled with 4-chlorosulfonyl-2,1,3- benzothiadiazole in pyridine to afford II (74%). The latter showed binding to CCK2R specific zinc finger proteins fused with the herpes simplex virus VP16 activation domain with pKi of 7.6 and behaved as a competitive antagonist in a guinea pig gastric corpeal muscle assay with pKB of 8.8. Thus, I and their pharmaceutical compns. are useful for the treatment of CCK2 mediated conditions, such as pancreatic adenocarcinoma, pain, eating disorders, gastroesophageal reflux disease, gastroduodenal ulcers, reflux esophagitis, anxiety, colon cancer, peptic ulcers, pancreatic tumors, gastric tumors, Barrett's esophagus, antral G cell hyperplasia, pernicious anemia, and Zollinger-Ellison syndrome (no data).

IT 791099-02-0P, 2-[[[(2,1,3-Benzothiadiazol-4-yl)sulfonyl]amino]-4-chloro-N-(2-methylsulfanylbenzyl)benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(CCK2 modulator; preparation of [[(benzo[1,2,5]thiadiazol-4-yl)sulfonyl]amino]benzamides as CCK2 modulators for treatment of gastrointestinal disorders, pain, and other conditions)

RN 791099-02-0 .CAPLUS

CN Benzamide, 2-[(2,1,3-benzothiadiazol-4-ylsulfonyl)amino]-4-chloro-N-[[2-(methylthio)phenyl]methyl]- (9CI) (CA INDEX NAME)



L35 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:931583 CAPLUS Full-text

DOCUMENT NUMBER: 141:396980

TITLE: Coloring compositions, dispersions containing them and their use in thermal transfer and ink-jet printing inks and printing method

INVENTOR(S): Takahashi, Mari; Suzuki, Takashi; Ikemizu, Hiroshi; Ikesu, Satoru

PATENT ASSIGNEE(S): Konica Minolta Holdings, Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 74 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2004307633	A	20041104	JP 2003-102763	20030407
PRIORITY APPLN. INFO.:			JP 2003-102763	20030407

OTHER SOURCE(S): MARPAT 141:396980



AB The compns. having high-d. black color, can form images with good light resistance and stability, contain bisazo compds. of Q1N=NZN=NQ2 (Q1, Q2 = aromatic groups; Z = 5- or 6-membered N-containing heterocyclic rings), and can be formulated with (preferably oil-soluble) polymers which become shell components of coloring microparticles, and organic solvents having b.p. higher than 150°.

IT 786697-02-7

RL: TEM (Technical or engineered material use); USES (Uses)
(dyes; coloring compns. with good light resistance and high d.,
dispersions containing them and their use in thermal transfer and ink-jet
printing inks)

RN 786697-02-7 CAPLUS

CN 1,3,5-Benzenetrisulfonic acid, 2-[[5-[[6-[[2-[(dodecylsulfonyl)amino]benzo
yl]amino]-1,2,3,4-tetrahydro-5-hydroxy-4,4-dimethyl-2-oxo-8-
quinolinyl]azo]-4-methyl-1H-pyrrol-3-yl]azo]-, trisodium salt (9CI) (CA
INDEX NAME)





●3 Na

L35 ANSWER 13 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:756698 CAPLUS Full-text
 DOCUMENT NUMBER: 141:277632
 TITLE: Preparation of quinazolines as modulators of ion channels
 INVENTOR(S): Gonzales, Jesus E., III; Wilson, Dean Mitchell; Termin, Andreas Peter; Grootenhuis, Peter Diederik Jan; Zhang, Yulian; Petzoldt, Benjamin John; Fanning, Lev Tyler Dewey; Neubert, Timothy Donald; Tung, Roger D.; Martinborough, Esther; Zimmermann, Nicole
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 565 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

WO 2004078733	A1	20040916	WO 2004-US6451	20040303
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004217891	A1	20040916	AU 2004-217891	20040303
CA 2517844	A1	20040916	CA 2004-2517844	20040303
EP 1608632	A1	20051228	EP 2004-716887	20040303
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
BR 2004008026	A	20060207	BR 2004-8026	20040303
CN 1784391	A	20060607	CN 2004-80011981	20040303
JP 2006522119	T	20060928	JP 2006-509028	20040303
NO 2005004546	A	20051125	NO 2005-4546	20051003
IN 2005KN01955	A	20061124	IN 2005-KN1955	20051003
PRIORITY APPLN. INFO.:			US 2003-451458P	P 20030303
			US 2003-463797P	P 20030418
			WO 2004-US6451	A 20040303

OTHER SOURCE(S): MARPAT 141:277632
GI



AB The title compds. [I; NR1R2 = (un)substituted 3-12 membered monocyclic or bicyclic (un)saturated ring having 0-3 heteroatoms selected from N, S or O; ring A = (un)substituted 5-7 membered aryl or 8-10 membered bicyclic aryl having 0-3 heteroatoms selected from N, S or O; x = 0-4; R3 = QR (wherein Q = a bond, alkylidene wherein up to two non-adjacent methylene units are optionally replaced by S, O, CS, etc.; R = halo, NO2, CN, etc.)], useful as inhibitors of voltage-gated sodium channels and calcium channels, were prepared. Thus, reacting 2-(4-chloro-7-methylquinazolin-2-yl)phenol with 4-aminopiperidine in the presence of Et3N in CH2Cl2 afforded 89% II. Representative compds. I were found to possess desired N-type calcium channel modulation activity and selectivity (no specific data given). Also, representative compds. I were found to possess desired voltage gated sodium channel activity and selectivity (no specific data given). The invention also provides pharmaceutically acceptable compns. comprising the compds. I and methods of using the compns. in the treatment of various disorders.

IT 757991-61-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolines as modulators of ion channels)

RN 757991-61-0 CAPLUS

CN Methanesulfonamide, N-[2-[4-[4-(butylsulfonyl)-1-piperazinyl]-7-methyl-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 14 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:271954 CAPLUS Full-text

DOCUMENT NUMBER: 140:294701

TITLE: Silver halide color photographic material containing specific coupler

INVENTOR(S): Mizukawa, Hiroki; Sano, Satoshi; Kawagishi, Toshio

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 83 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent



LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004101649	A	20040402	JP 2002-260323	20020905
PRIORITY APPLN. INFO.:			JP 2002-260323	20020905

GI



AB The photog. material contains a coupler bearing ≥ 1 substituent Q1 in a mol. (A = NR4; R4 = H, alkyl, aryl; m = 0, 1; R1 = substituent; n = 0-3; R2-3 = alkyl, alkenyl, aryl) except I (R8 = H, substituent; X2 = H, releasing group on the


reaction with developer oxide; Za = N:, Zb = :CR9; R9 links to Q1 through aralkylene group). The coupler shows good solubility in high b.p. organic solvent, elution from the organic solvent drop is prevented on development, and the material gives high d. images without bad effect to Ag development.

IT 676236-99-0 676237-00-6

RL: TEM (Technical or engineered material use); USES (Uses)
(photog. film containing coupler with benzenesulfonamide group)


RN 676236-99-0 CAPLUS

CN Benzamide, N-[3-[[[1-[6-(1,1-dimethylethyl)-1H-pyrrolo[2,1-c]-1,2,4-triazol-3-yl]ethyl]amino]sulfonyl]-4,5-bis(dodecyloxy)phenyl]-2-[[4-methylphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 676237-00-6 CAPLUS

CN Benzamide, N-[3-[[[2-[6-(1,1-dimethylethyl)-1H-pyrrolo[2,1-c]-1,2,4-triazol-3-yl]-1,1,2-trimethylpropyl]amino]sulfonyl]-4,5-bis(dodecyloxy)phenyl]-2-[[4-methylphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



L35 ANSWER 15 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:767966 CAPLUS Full-text

DOCUMENT NUMBER: 139:299157

TITLE: Azo dyes for silver halide color photographic

materials
 INVENTOR(S): Nakano, Aiko; Fukagawa, Nobutaka; Ito, Takayuki
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 32 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003277638	A	20031002	JP 2002-81807	20020322
PRIORITY APPLN. INFO.:			JP 2002-81807	20020322
OTHER SOURCE(S):	MARPAT 139:299157			

AB The dyes comprise 1H-pyrazolo[5,1-c]-1,2,4-triazoles selected from 3 kinds of Markush structures specified in the document. The dyes show good absorption characteristics and high resistance to light, heat, moisture, air, and chems.


IT 608513-62-8 608513-64-0

RL: TEM (Technical or engineered material use); USES (Uses)
 (pyrazolotriazole dyes with good absorption characteristics for color photog. materials)

RN 608513-62-8 CAPLUS

CN Benzenesulfonamide, N-[5-(1,1-dimethylethyl)-4-(hexadecyloxy)-2-hydroxyphenyl]-3-[5-[[6-ethyl-3-[4-methoxy-2-[(methylsulfonyl)amino]phenyl]-1H-pyrazolo[5,1-c]-1,2,4-triazol-7-yl]azo]-1,2,4-oxadiazol-3-yl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


U

RN 608513-64-0 CAPLUS
 CN Benzenesulfonamide, N-[5-(1,1-dimethylethyl)-4-(hexadecyloxy)-2-hydroxyphenyl]-5-[[[3-[5-[6-ethyl-3-[4-methoxy-2-(methylsulfonyl)amino]phenyl]-1H-pyrazolo[5,1-c]-1,2,4-triazol-7-yl]azo]-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]amino]-2-(2-methoxyethoxy)- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



L35 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:711891 CAPLUS Full-text
 DOCUMENT NUMBER: 139:237617
 TITLE: Silver halide color photographic material containing pyrazolotriazole-type magenta coupler
 INVENTOR(S): Mizukawa, Hiroki; Fukuzawa, Hiroshi; Kawakishi, Toshio; Tsukase, Masaaki
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 78 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003255499	A	20030910	JP 2002-367186	20021218
US 2004101792	A1	20040527	US 2002-329466	20021227
US 6770431	B2	20040803		
PRIORITY APPLN. INFO.:			JP 2001-401228	A 20011228
OTHER SOURCE(S):	MARPAT 139:237617			
GI				



AB The photog. material contains 1H-pyrazolo[3,2-c]-1,2,5-triazole-type coupler substituted with aromatic group I (R₁ = substituent; R₂ = alkyl, alkenyl, aryl; m = 0-4). Alternatively, the material contains ≥1 coupler selected from pyrazolotriazole II and III (R₈ = substituent; X₂ = H, group leaving in reaction with oxidized developer; L₂ = alkylene, aralkylene; Z₁ = CO₂, NRCO, NRCO₂, etc; R = H, alkyl, aryl; Y₁ = divalent linking group; q = 0, 1; R₁₁, R₁₂ = H, alkyl, aryl; A₁ = aromatic group). The material shows stable magenta color image formation under change of composition of treatments, e.g., developer, etc., and retention of color-forming property in reduced amts. of high-b.p. organic solvents in development, fixing, etc.


IT 595583-55-4 595583-57-6 595583-59-8
595583-60-1 595584-03-5

RL: MOA (Modifier or additive use); USES (Uses)

(pyrazolotriazole-type magenta coupler for photog. emulsion)


RN 595583-55-4 CAPLUS

CN Benzamide, N-[1-[6-(1,1-dimethylethyl)-1H-pyrazolo[5,1-c]-1,2,4-triazol-3-yl]ethyl]-5-[2-[(methylsulfonyl)amino]benzoyl]amino]-2-(octadecylthio)-(9CI) (CA INDEX NAME)




RN 595583-57-6 CAPLUS

CN Benzamide, N-[1-[7-chloro-6-(1,1-dimethylethyl)-1H-pyrazolo[5,1-c]-1,2,4-triazol-3-yl]ethyl]-2-(hexadecylsulfonyl)-5-[[2-[[4-methylphenyl)sulfonyl]amino]benzoyl]amino]- (9CI) (CA INDEX NAME)




RN 595583-59-8 CAPLUS

CN Benzoic acid, 5-[[2-[[[4-(2-methylpropyl)phenyl)sulfonyl]amino]benzoyl]amino]-2-(octadecylsulfonyl)-, 2-[6-(1,1-dimethylethyl)-1H-pyrazolo[5,1-c]-1,2,4-triazol-3-yl]-2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 595583-60-1 CAPLUS

CN Benzamide, N-[2-[6-(1,1-dimethylethyl)-1H-pyrazolo[5,1-c]-1,2,4-triazol-3-yl]-1,1,2-trimethylpropyl]-5-[[2-[[4-methylphenyl)sulfonyl]amino]benzoyl]amino]-2-(octadecylsulfonyl)- (9CI) (CA INDEX NAME)



RN 595584-03-5 CAPLUS
 CN Benzamide, N-[2-[6-(1,1-dimethylethyl)-1H-pyrazolo[5,1-c]-1,2,4-triazol-3-yl]-1,1,2-trimethylpropyl]-5-[[2-[(methylsulfonyl)amino]benzoyl]amino]-2-(octadecylsulfonyl)- (9CI) (CA INDEX NAME)



L35 ANSWER 17 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:551386 CAPLUS Full-text
 DOCUMENT NUMBER: 139:117209
 TITLE: Preparation of biaryl phosphate transport inhibitors
 INVENTOR(S): Jozefiak, Thomas H.; Bastos, Cecilia M.; Papoulis, Andrew T.; Holmes-Farley, Stephen Randall
 PATENT ASSIGNEE(S): Genzyme Corporation, USA
 SOURCE: PCT Int. Appl., 135 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057225	A2	20030717	WO 2002-US41481	20021224
WO 2003057225	A3	20040408		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004019113 A1 20040129 US 2002-327627 20021220

US 7119120 B2 20061010

AU 2002367396 A1 20030724 AU 2002-367396 20021224

EP 1465638 A2 20041013 EP 2002-806234 20021224

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

JP 2005514413 T 20050519 JP 2003-557583 20021224

US 2007021509 A1 20070125 US 2006-489286 20060719

PRIORITY APPLN. INFO.: US 2001-344660P P 20011226


US 2002-371649P P 20020410

US 2002-327627 A1 20021220

WO 2002-US41481 W 20021224

OTHER SOURCE(S): MARPAT 139:117209

GI



II

AB Disclosed are compds. Ar1-W-X-Y-Ar2 [Ar1-2 = (un)substituted aryl group or 5-6
 membered non-aromatic group fused to a (un)substituted monocyclic aryl group;
 W, Y = covalent bond, alkylene; X = SO₂, SO₂-alkyl, SO₂-amino, etc; I] which
 are inhibitors of phosphate transport. For instance, 5-bromo-2-[[4-
 trifluoromethoxyphenyl)sulfonyl]amino]benzoic acid (preparation given) is
 converted to the acid chloride (SOCl₂, reflux) and used to acylate 2-
 methoxybenzyl amine (THF) to give II. Example compds. inhibit phosphate
 transport in rabbit intestinal brush border membrane vesicles; a select group
 of example compds. has IC₅₀ = 0-50 μM. I are used to treat a disease
 associated with hyperphosphatemia, as well as a disease mediated by phosphate-
 transport function.


IT 562078-57-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of biaryl phosphate transport inhibitors)



RN 562078-57-3 CAPLUS

CN Benzamide, 5-bromo-N-[4-(methylthio)phenyl]-2-[[[4-
 (trifluoromethoxy)phenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



L35 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:594806 CAPLUS Full-text
 DOCUMENT NUMBER: 137:154762
 TITLE: Preparation of N-[2-(cycloalkylamino)-2-oxoethyl]benzamides and related compounds as modulators of chemokine receptor activity
 INVENTOR(S): Cherney, Robert
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 286 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060859	A2	20020808	WO 2001-US50252	20011220
WO 2002060859	A3	20030327		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2432369	A1	20020808	CA 2001-2432369	20011220
US 2003004151	A1	20030102	US 2001-27644	20011220
US 6706712	B2	20040316		
EP 1343751	A2	20030917	EP 2001-997125	20011220
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
HU 200303652	A2	20040301	HU 2003-3652	20011220
JP 2004523534	T	20040805	JP 2002-561010	20011220
US 2004110736	A1	20040610	US 2003-706448	20031112
US 7045521	B2	20060516		
US 2006135502	A1	20060622	US 2005-315385	20051222
PRIORITY APPLN. INFO.:			US 2000-256904P	P 20001220
			US 2001-27644	A3 20011220
			WO 2001-US50252	W 20011220
			US 2003-706448	A3 20031112
OTHER SOURCE(S):	MARPAT 137:154762			
GI				



AB Title compds. I [wherein; or pharmaceutically acceptable salts thereof] were prepared as modulators of chemokine receptor activity, especially monocyte chemoattractant protein-1 (MCP-1) (no data). For example, N-tert-butoxycarbonylcyclohexane-(S,S)-1,2-diamine was treated with 4-methylmorpholine and [[3-(trifluoromethyl)benzoyl]amino]acetic acid in DMF to give the amide. Deprotection using TFA in CH₂Cl₂, followed by sequential addition of Hunig's base, 4-chlorobenzaldehyde, and NaHB(OAc)₃, afforded the [(cyclohexylamino)oxoethyl]benzamide II. I are useful for the treatment and prevention of inflammatory disease, allergic and autoimmune diseases, and in particular, rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma (no data).

IT **445479-99-2P**, 2-[(Methylsulfonyl)amino]-N-[2-[[cis-2-[[4-(aminosulfonyl)benzoyl]amino]cyclohexyl]amino]-2-oxoethyl]-5-(trifluoromethyl)benzamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(chemokine receptor modulator; preparation of [(cycloalkylamino)oxoethyl]benzamides and related compds. as modulators of chemokine receptor activity)

RN 445479-99-2 CAPLUS

CN Benzamide, N-[2-[[[(1R,2S)-2-[[4-(aminosulfonyl)benzoyl]amino]cyclohexyl]amino]-2-oxoethyl]-2-[(methylsulfonyl)amino]-5-(trifluoromethyl)-, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



L35 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:63629 CAPLUS Full-text
 DOCUMENT NUMBER: 136:142541
 TITLE: Phenol azo dye in silver halide photographic films
 INVENTOR(S): Katsumata, Taiji; Uchida, Osamu
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 52 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002020642	A	20020123	JP 2000-208647	20000710
PRIORITY APPLN. INFO.:			JP 2000-208647	20000710
OTHER SOURCE(S):	MARPAT 136:142541			

GI




AB The invention relates to a phenol azo dye I (R1 = alkyl, alkoxy, amino, etc.; R2, R4 = H, substituent; R3 = alkyl, aryl; R5 = aryl, aromatic heterocyclics). The dye shows the good optical characteristics and the high durability.


IT **391865-65-9P 391865-66-0P**
 RL: SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (phenol azo dye in silver halide photog. films)

RN 391865-65-9 CAPLUS


CN Benzamide, 4-[5-(1,1-dimethylethyl)-4-[[4-[[[3-[5-[4-hydroxy-2-methoxy-5-[[2-[(methylsulfonyl)amino]benzoyl]amino]phenyl]azo]-1,2,4-thiadiazol-3-yl]phenyl]sulfonyl]amino]phenoxy]methyl]-3-oxo-2(3H)-isoxazolyl]-N-hexadecyl-3-nitro- (9CI) (CA INDEX NAME)

PAGE 1-A





RN 391865-66-0 CAPLUS
 CN Benzamide, N-[5-[[3-[3-[[[5-cyclohexyl-4-(hexadecyloxy)-2-hydroxyphenyl]amino]sulfonyl]phenyl]-1,2,4-thiadiazol-5-yl]azo]-2-hydroxy-4-methoxyphenyl]-2-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



— (CH₂)₁₅—Me

L35 ANSWER 20 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:837010 CAPLUS Full-text
 DOCUMENT NUMBER: 134:34994
 TITLE: Photographic lipophilic fine particle dispersion liquid, photographic material, and image formation
 INVENTOR(S): Hiyama, Kunimasa
 PATENT ASSIGNEE(S): Konica Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 66 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000330239	A	20001130	JP 1999-143205	19990524
PRIORITY APPLN. INFO.:			JP 1999-143205	19990524
OTHER SOURCE(S):	MARPAT 134:34994			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The title dispersion liquid contains a compound I (R1, R2 = alkyl, aryl, alkoxy, aryloxy; R3 = H, halo, univalent organic group) or II [R1, R2 = substituent, ≥ 1 of R1 and R2 is alkoxy, aryloxy, alkylthio, acylamino, or NHCO_2R (R = alkyl, aryl); X1, X2 = halo; m, n, p, q = 0-4, m + n, p + q = 0-4, m \neq n \neq 0, when m, n, p, q ≥ 2 , the plural groups of R1, R2, X1, and X2 are the same or different] or ≥ 1 compound (A) having an absorption maximum wavelength in the range of 330-390 nm and a molar extinction coefficient of ≥ 17000 and the average particle diameter of the dispersed lipophilic fine particles is $\leq 0.1 \mu\text{m}$ or the refractive index of the oil phase is 1.48-1.58. Photog. material, having ≥ 1 photosensitive layer and ≥ 1 nonphotosensitive layer, contains I, II, and (i) the compound (A) and a nonionic surfactant, (ii) ≥ 1 selected from III (R31 = C1-3 alkyl, R32 = ballast group; X21 = releasing group by reaction with developer oxide), IV, V, VI, and VII (R42 = substituent; R41, R43, R46-47 = H, substituent; Z1, Z3 = nonmetal atoms to form 5-membered N-containing heterocycle; Z2, Z4 = nonmetal atoms to form 6-membered N-containing heterocycle; R44-45 = electron withdrawing group; X31-34 = releasing group by reaction with developer oxide) (iii) aliphatic alc., (iv) VIII (R12-13 = sec- or tert-alkyl), (v) tabular silver halide emulsion with AgCl content $\geq 95 \text{ mol}\%$ and aspect ratio ≥ 3.0 , (vi) a fluorescent brightener in a support, (vii) Ag halide emulsion with AgCl content $\geq 95 \text{ mol}\%$ and containing Ir compound, or (viii) fluorosurfactant. The photog. material containing I or II is subjected to scanning exposure using laser beams having an emission maximum at 400-450 nm to form images. The dispersion liquid shows high lightfastness and color d. even after storage and the photog. material provides high quality color images showing little variation of Dmin and discoloration upon rapid processing.

IT 172972-51-9

RL: DEV (Device component use); USES (Uses)
(coupler; photog. paper containing UV absorbent)

RN 172972-51-9 CAPLUS

CN Propanoic acid, 3-[[3-[2-[[[4-(dodecyloxy)phenyl]sulfonyl]amino]phenyl]-6-[(phenylamino)carbonyl]-1H-pyrazolo[5,1-c]-1,2,4-triazol-7-yl]thio]- (9CI)
(CA INDEX NAME)



L35 ANSWER 21 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:205750 CAPLUS Full-text


DOCUMENT NUMBER: 132:243879

TITLE: Silver halide color photographic material with good color reproduction

INVENTOR(S): Kaneko, Yutaka; Ikesu, Satoru; Suzuki, Takashi
 PATENT ASSIGNEE(S): Konica Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 36 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000089421	A	20000331	JP 1998-253791	19980908
PRIORITY APPLN. INFO.:			JP 1998-253791	19980908
OTHER SOURCE(S):	MARPAT 132:243879			

GI



AB The title photog. material, possessing photog. constitutive layers including blue-sensitive, green-sensitive, and red-sensitive Ag halide emulsion layers, contains (i) a cyan coupler I, II or III [R¹, R³ = C₁-32 alkyl, aryl, heterocyclic group, alkoxy, hetrocycleoxy (these groups may be substituted); R², R⁴ = substituent; R²², R²³ = electron-attracting group with Hammett's substituent constant $\sigma_p \geq 0.30$; Z⁵ = nonmetal atoms required to form an azole ring containing N as the hetero atm; X¹, X², X⁵ = H, halo, group releasing upon reaction with an oxidized color developing agent] in the red-sensitive layer and (ii) a yellow coupler IV (R⁵ = aliphatic or aromatic group; R⁶ = anti-diffusive aliphatic or aromatic group; Y = H, substituent; n = 1-4; X³ = 5- or 6-membered heterocyclic group releasing upon reaction with an oxidized color developing agent) in the blue-sensitive layer and/or (iii) a magenta coupler V [R²⁰ = substituent; R²¹ = (substituted) alkyl, cycloalkyl, aryl; L = (substituted) alkylene; J = CO, SO₂; X⁴ = H, halo, group releasing upon reaction with an oxidized color developing agent; Z⁴ = nonmetal atoms required to form a N-containing heterocycle] in the green-sensitive layer. The material shows improved color reproducibility and coloring properties and

provides high quality color images with good lightfastness, thermal resistance, and moisture resistance.

IT 261906-70-1


RL: DEV (Device component use); USES (Uses)

(cyan coupler; photog. film containing pyrazolotriazole cyan coupler, phenol derivative yellow coupler, and pyrazolotriazole magenta coupler)

RN 261906-70-1 CAPLUS

CN 1H-Pyrrolo[1,2-b][1,2,4]triazole-7-carboxylic acid, 6-cyano-2-[4-methyl-3-[[[2-[2-[2-[(phenylsulfonyl)amino]benzoyl]amino]ethoxy]-5-(1,1,3,3-tetramethylbutyl)phenyl]sulfonyl]amino]phenyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylcyclohexyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

L35 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:68451 CAPLUS Full-text
DOCUMENT NUMBER: 132:93335
TITLE: Preparation of pyrimidine derivatives as antitumor agents
INVENTOR(S): Ueda, Kazuo; Tanaka, Hidekazu; Takenaka, Hideyuki
PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.


KIND

DATE

APPLICATION NO.

DATE

WO 2000004014	A1	20000127	WO 1999-JP3863	19990716
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2336832	A1	20000127	CA 1999-2336832	19990716
AU 9945640	A1	20000207	AU 1999-46540	19990716
AU 748816	B2	20020613		
EP 1097933	A1	20010509	EP 1999-929886	19990716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TW 548275	B	20030821	TW 1999-88112093	19990716
ZA 2001000283	A	20020110	ZA 2001-283	20010110
US 6420367	B1	20020716	US 2001-743721	20010116
PRIORITY APPLN. INFO.:			JP 1998-201423	A 19980716
			JP 1999-110320	A 19990419
			WO 1999-JP3863	W 19990716
OTHER SOURCE(S):			MARPAT 132:93335	
GI				




AB Title compds. I (R1, R2, R3, R4 = H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, acyl, etc.; R5, R6 = H, alkyl, alkenyl, alkynyl, alkyloxy, alkylthio, etc.; X = O, S, etc.; Y = a divalent group derived from a five-membered aromatic heterocycle, etc.; Z = optionally substituted aryl, heteroaryl, etc.) and their salts or solvates, useful as antitumor agents, are prepared. Thus, I (R1 = R3 = R6 = H, R2 = R5 = Me, R4 = Et, R5; X = S, Y = oxadiazolyl, Z = 2-H2NC6H4) (II) was prepared in several steps from Et 2-methyl-3-amino-4-pyrimidinecarboxylate and 2-(2-aminophenyl)-5-mercapto-1,3,4-oxadiazole. II showed in vitro antineoplastic activity against various tumor cells. Formulations containing I were given.

IT **254969-39-6P 254969-54-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. as antitumor agents)


RN 254969-39-6 CAPLUS

CN Benzenesulfonamide, N-[2-[5-[[[4-[[amino(ethylamino)methylene]amino]-2-methyl-5-pyrimidinyl]methyl]thio]-1,3,4-oxadiazol-2-yl]phenyl]-4-methoxy-(9CI) (CA INDEX NAME)



RN 254969-54-5 CAPLUS

CN Methanesulfonamide, N-[2-[5-[[[4-[(ethylamino)(methylamino)methylene]amino]-2-methyl-5-pyrimidinyl]methyl]thio]-1,3,4-oxadiazol-2-yl]phenyl]- (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 23 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:614114 CAPLUS Full-text

DOCUMENT NUMBER: 131:336969

TITLE: Synthesis and structure-activity relationships of novel small molecule cathepsin D inhibitors

AUTHOR(S): Dumas, Jacques; Brittelli, David; Chen, Jinshan; Dixon, Brian; Hatoum-Mokdad, Holia; Konig, Gerhard; Sibley, Robert; Witowsky, James; Wong, Stephen
CORPORATE SOURCE: Department of Chemistry Research, Pharmaceutical Division, Bayer Corporation, West Haven, CT, 06516, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1999), 9(17), 2531-2536


CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Cathepsin D, a lysosomal aspartyl protease, has been implicated in the pathol. of Alzheimer's disease as well as breast and ovarian cancer. A weakly active cathepsin D inhibitor was identified by high throughput screening. Subsequent optimization led to the discovery of a new class of small mol. inhibitors of this enzyme, culminating with the sulfonamide I (IC₅₀ = 250 nM).


IT **250124-69-7P 250124-71-1P 250125-31-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

((benzamidophenyl)thio]benzothiazoles and related compds. as cathepsin D inhibitors)


RN 250124-69-7 CAPLUS

CN Benzoic acid, 2-[[[4-chloro-2-[[[4-[(6-ethoxy-2-benzothiazolyl)thio]phenyl]amino]carbonyl]phenyl]amino]sulfonyl]- (9CI)
(CA INDEX NAME)




RN 250124-71-1 CAPLUS

CN Benzamide, 3,5-dichloro-2-[[[(3,5-dichloro-2-hydroxyphenyl)sulfonyl]amino]-N-[4-[(6-ethoxy-2-benzothiazolyl)thio]phenyl]- (9CI) (CA INDEX NAME)




RN 250125-31-6 CAPLUS
 CN Benzoic acid, 3-[[[4-chloro-2-[[[4-[(6-ethoxy-2-benzothiazolyl)thio]phenyl]amino]carbonyl]phenyl]amino]sulfonyl]- (9CI)
 (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:493875 CAPLUS Full-text
 DOCUMENT NUMBER: 129:168052
 TITLE: Silver halide color photographic material containing a pyrroloazole coupler
 INVENTOR(S): Yamazaki, Takayasu
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 46 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10198011	A	19980731	JP 1997-15916	19970113
PRIORITY APPLN. INFO.:			JP 1997-15916	19970113
OTHER SOURCE(S):		MARPAT 129:168052		
GI				



AB Claimed color photog. material having a support and a component layer containing an Ag halide emulsion, a developing agent, a compound to form a dye by coupling with the oxidized developing agent and the binder, which develop color image by being contacted with the processing sheet containing a base or base precursor followed by heating the stack, is characterized in (1) that at least one of the emulsion contains, in the amount of 50% of total projected area, AgCl-dominant (AgCl \geq 50 mol%) tabular grains with (100) surface and aspect ratio of \geq 2.0, and (2) that a pyrroloazole compound I (Z = azole ring; R1, R2 = electron-attracting group with Hammett's $\sigma_p \geq 0.3$, X = H, leaving group to be released by the coupling reaction with the oxidized developing agent). The photog. material is thermally processed without using a developer solution. Compound I is a cyan coupler with high developability and low fog. Thus, coupler I (Z = 3-[4-(2-octyl-5-octyloxy-phenylsulfoamino)-2-methyl-phenoxyethyl]-1,2,4-triazole ring; R1 = methoxycarbonyl; R2 = CN; X = H) was incorporated in the thermal development type color photog. material.


IT 211053-71-3

RL: DEV (Device component use); USES (Uses)

(coupler; color photog. material containing pyrroloazole coupler to improve speed/fog ratio and color developability)

RN 211053-71-3 CAPLUS

CN 1H-Pyrrolo[1,2-b][1,2,4]triazole-7-carboxylic acid, 6-cyano-2-[4-methyl-3-[[[2-[2-[[2-[(phenylsulfonyl)amino]benzoyl]amino]ethoxy]-5-(1,1,3,3-tetramethylbutyl)phenyl]sulfonyl]amino]phenyl]-, cyclohexyl ester (9CI)
(CA INDEX NAME)



L35 ANSWER 25 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:8789 CAPLUS Full-text

DOCUMENT NUMBER: 128:121624

TITLE: Silver halide color photographic material with mordant layer and peelable layer and the imaging process

INVENTOR(S): Makuta, Toshiyuki; Nakamura, Takemare

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 74 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09329878	A	19971222	JP 1996-174329	19960613
PRIORITY APPLN. INFO.:			JP 1996-174329	19960613
OTHER SOURCE(S):	MARPAT 128:121624			


AB Claimed photog. material having ≥ 1 Ag halide emulsion layer and ≥ 1 light-insensitive hydrophilic colloid layer on a support is characterized by (1) that the component layers contain a hydrazine derivative QNHNH₂ (Q = unsatd. ring; Z = carbamoyl, acyl, alkoxy-carbonyl, aryloxy-carbonyl), a diffusible dye-forming coupler and a mordant and (2) that at least one of the light-insensitive layer is a peelable layer. Also claimed is the image-forming method comprising imagewise exposure followed by development by an alkaline solution free of developing agent. The processing does not need bleach and fixing stages, and contains treatment by an amplifier solution. The color image is fixed on the mordant layer which is separated from the developed emulsion layer, consequently the completed image is free from dye stain. In the example, a color photog. layer composite containing 1-(2-ethyl-4-dodecyloylamido-phenoxypropylaminocarbonyl)-2-(2-methylsulfo-4,5-di-cyano-phenyl)hydrazine (reducing agent) and 1-[1-cyano-1-(2-chloro-5-methoxycarbonyl-anilinocarbonyl) methoxy]-benzene-4-dodecylamide (coupler) and a piperidinium-grafted poly(vinylbenzene) (mordant) was used in the claimed image-forming process.

IT 201683-31-0

RL: DEV (Device component use); USES (Uses)
 (coupler; color photog. material with mordant layer and peelable layer to provide stain-free color image and imaging process)





RN 201683-31-0 CAPLUS

CN Benzenesulfonamide, 4-[[6-ethyl-3-[4-methoxy-2-[(methylsulfonyl)amino]phenyl]-1H-pyrazolo[5,1-c]-1,2,4-triazol-7-yl]oxy]-N-octadecyl- (9CI) (CA INDEX NAME)



DOCUMENT NUMBER: 126:257007
 TITLE: Silver halide color photographic material with excellent color reproduction, sharpness and storage stability
 INVENTOR(S): Matsumoto, Keisuke; Morigaki, Masakazu
 PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 88 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09043786	A	19970214	JP 1995-211297	19950728
PRIORITY APPLN. INFO.: GI			JP 1995-211297	19950728




AB In the title material including a yellow filter layer, the material contains a reducing agent(s) selected from I, II, R₁C₁R₂C₃N, III and IV [R₁m, R₂m, R₁n, R₂n = H, alkyl; R₃m, R₃n = H, alkyl, aryl; R₄m, R₄n = aryl; R₅n = alkyl, aryl, alkoxy, aryloxy, alkylamino, arylamino; R₁ = OH, NR₂'R₃'; R₂, R₃, R₂', R₃' = H, alkyl, aryl; R₂-R₃, R₂-R₂' and R₂'-R₃' may form 5- or 6-membered ring; R_d1 = C₁₀-40 alkyl; R_e1 = alkoxy, aryloxy, alkylamino, arylamino] and a photog. DIR coupler Red-Ln-Gm-(Time)t-X [Red = group capable of releasing -(Time)t-X upon oxidation; Time = timing group capable of releasing -X; X = development inhibitor; L = divalent connection group; G = acidic group; n, m, t = 0, 1].

IT 151691-43-9

RL: MOA (Modifier or additive use); USES (Uses)
 (photog. DIR coupler)


RN 151691-43-9 CAPLUS

CN Benzamide, N-[2,5-dihydroxy-4-[[5-(methylthio)-1,3,4-thiadiazol-2-yl]thio]phenyl]-2-[(hexadecylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L35 ANSWER 27 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:437556 CAPLUS Full-text
 DOCUMENT NUMBER: 125:100016
 TITLE: Silver halide color photographic material containing
 benzotriazine to improve image quality
 INVENTOR(S): Ooki, Nobutaka; Fukagawa, Nobutaka
 PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 46 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08095213	A	19960412	JP 1994-251592	19940921
PRIORITY APPLN. INFO.:			JP 1994-251592	19940921
OTHER SOURCE(S):	MARPAT 125:100016			
GI				




AB The claimed Ag halide color photog. material contains a reducing agent I (R1-4 = H, electron-attractive group; at least one of R1 or R4 is not H; R5 = H, alkyl, alkoxy, aryl). Preferably, the substituent R5 is a group -(TIME)tPUG where TIME is a timing group to control the time for releasing PUG, PUG is a photog. useful leaving group, and t is 0 or 1. The compound improves photog. performance by scavenging an oxidized substance and/or releasing, during development, the development inhibitor, accelerator or other useful compound incorporated in R5.

IT **178766-52-4**
 RL: DEV (Device component use); USES (Uses)
 (silver halide color photog. material containing benzotriazine to improve image quality)






RN 178766-52-4 CAPLUS
 CN 1-Hexadecanesulfonamide, N-[2-[7-chloro-1,2-dihydro-6-(methylsulfonyl)-

1,2,4-benzotriazin-3-yl]phenyl]- (9CI) (CA INDEX NAME)



L35 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1995:986740 CAPLUS Full-text
 DOCUMENT NUMBER: 124:160215
 TITLE: Direct-positive color photographic material and image-forming method
 INVENTOR(S): Sasagawa, Masayuki; Ookawachi, Susumu
 PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 31 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07253630	A	19951003	JP 1994-44104	19940315
PRIORITY APPLN. INFO.: GI			JP 1994-44104	19940315



AB The photog. material comprises a support coated with a Ag halide emulsion layer containing non-prefogged internal latent image-type Ag halide particles and I (Z1-2 = nonmetal atoms to form 5- or 6-membered heterocycle; L1 =


methine group; R1 = J2COOH; J1-2 = alkylene; 1, m = 0, 1; n ≥ 3), and photog. constitution layers on the same side as the emulsion layer has the swelling degree 80-200%. The material may contain ≥ 1 of II-V (R1 = H, substituent; R2 = substituent; when m = 0, R1 = electron-attractive group with Hammett σ_p ≥ 0.20; when m = 1 or 2 ≥ 1 of R1-2 = electron-attractive group with σ_p ≥ 0.20; Z1, Z3 = nonmetal atoms to 5-membered heterocycle; R3 = H, substituent; Z2, Z4 = nonmetal atoms to form 6-membered ring; R4-5 = electron attractive group with σ_p ≥ 0.20; sum of σ_p 's of R4 and R5 ≥ 0.65; X1-4 = H, releasing group by the coupling with oxidized developer). The material is imagewise exposed and developed at replenishing amount ≤ 700 mL/1 m² to form images. The material has less residual color and gives clear pos. images with good dot reproducibility.

IT 172972-51-9

RL: DEV (Device component use); USES (Uses)
(photog. cyan coupler)

RN 172972-51-9 CAPLUS

CN Propanoic acid, 3-[[3-[2-[[[4-(dodecyloxy)phenyl]sulfonyl]amino]phenyl]-6-[(phenylamino)carbonyl]-1H-pyrazolo[5,1-c]-1,2,4-triazol-7-yl]thio]- (9CI)
(CA INDEX NAME)



L35 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1995:818613 CAPLUS Full-text
 DOCUMENT NUMBER: 123:213269
 TITLE: Diffusion transfer heat processable photosensitive material.
 INVENTOR(S): Tomotake, Atsushi; Takiyama, Nobuyuki; Ohbayashi, Keiji
 PATENT ASSIGNEE(S): Konica Corp., Japan
 SOURCE: Eur. Pat. Appl., 37 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 656562	A2	19950607	EP 1994-308880	19941130
R: DE, FR, GB				
JP 07209835	A	19950811	JP 1994-298354	19941201
PRIORITY APPLN. INFO.:			JP 1993-304296	A 19931203
OTHER SOURCE(S):	MARPAT 123:213269			


AB A diffusion transfer heat-processable photosensitive material comprises a dye-providing material represented by [A-(J1)a-(X1)b]c-(J2)d-(X2)e-Dye [A = 1,3-S-

IT 168198-34-3


(cyan dye precursor for diffusion transfer heat processable
photosensitive material)


CN 1,3-Benzenedicarboxamide, N,N'-bis[2-[[[3-(5,5-dimethyl-3-octadecyl-2-thiazolidinyl)-4-hydroxyphenyl]sulfonyl]amino]ethyl]-5-[[[4-[1-[[[6-[4-[ethyl 2-[(methylsulfonyl)amino]ethyl]amino]-2-methylphenyl]imino]-4-[[2-[(methylsulfonyl)amino]benzoyl]amino]-3-oxo-1,4-cyclohexadien-1-yl]amino]carbonyl]propoxy]phenyl]sulfonyl]amino]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B





L35 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1995:696060 CAPLUS Full-text
 DOCUMENT NUMBER: 123:97775
 TITLE: Direct positive color photographic material, its development and color proofing using same
 INVENTOR(S): Fukagawa, Nobutaka; Ooki, Nobutaka
 PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 74 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07104447	A	19950421	JP 1993-264046	19930929
PRIORITY APPLN. INFO.: GI			JP 1993-264046	19930929




AB In the title full-color photog. material containing unrefogged internal-latent-image type Ag halide photog. emulsion, ≥1 of the component layers contains a specification defined coupler and a redox compound both of which will release a fogging agent or a development accelerator. The above color photog. material is developed with I (R1 = alkyl; R2 = alkylene; R1 and R2 may form a ring). This material increases the maximum d. of an image while maintaining its min. d., and is suitable for use in color proofing.

IT 163392-33-4

RL: DEV (Device component use); USES (Uses)
 (direct pos. color photog. material containing)


RN 163392-33-4 CAPLUS

CN Benzamide, 2-[(dodecylsulfonyl)amino]-N-[4-[[1-[3-[[[3-[[[4-(2-formylhydrazino)phenyl]amino]sulfonyl]phenyl]amino]carbonyl]amino]phenyl]-1H-tetrazol-5-yl]thio]-2,5-dihydroxyphenyl]- (9CI) (CA INDEX NAME)



L35 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1995:667304 CAPLUS Full-text
 DOCUMENT NUMBER: 123:70224
 TITLE: Direct positive color photographic material for color
 image formation and color proof
 INVENTOR(S): Fukagawa, Nobutaka; Ooki, Nobutaka
 PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 73 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07104421	A	19950421	JP 1993-248216	19931004
PRIORITY APPLN. INFO.: GI			JP 1993-248216	19931004



AB The title photog. material has ≥ 1 photosensitive layer and non-photosensitive layer containing hydroquinone compound I or II (RQ1-Q16 = specified organic group). Formation of color images and color proof is also claimed. The title material can give images with high-contrast, high maximum image d. and low min. image d.

IT 163392-42-5

RL: DEV (Device component use); USES (Uses)
(contained in pos. color photog. material)


RN 163392-42-5 CAPLUS

CN Acridinium, 7-[[[[[5-[[4-[[2-[(hexadecylsulfonyl)amino]benzoyl]amino]-2,5-dihydroxyphenyl]thio]-1,3,4-thiadiazol-2-yl]thio]acetyl]amino]-1,2,3,4-tetrahydro-10-(2-propynyl)-; salt with trifluoromethanesulfonic acid (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 163392-41-4


CMF C49 H61 N6 O6 S4



CM 2

CRN 37181-39-8

CMF C F3 O3 S




IT 163392-34-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(prepared and preparing specified compound for pos. color photog. material)

RN 163392-34-5 CAPLUS

CN Carbamic acid, [3-[5-[[4-[[2-[(dodecylsulfonyl)amino]benzoyl]amino]-2,5-dihydroxyphenyl]thio]-1H-tetrazol-1-yl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



L35 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:582653 CAPLUS Full-text

DOCUMENT NUMBER: 122:326365

TITLE: Direct positive silver halide photographic material and preparation of color proof

INVENTOR(S): Ozawa, Takashi

PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 58 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07036157	A	19950207	JP 1993-202949	19930723
PRIORITY APPLN. INFO.:			JP 1993-202949	19930723

GI For diagram(s), see printed CA Issue.

AB In the title photog. material comprising yellow, magenta, and cyan image-forming Ag halide emulsion overlaid layers having different spectral sensitivities and containing internal latent image-type Ag halide grains on a support, the overlaid layers comprise a Ag halide emulsion layer with a different hue from the others, and the yellow image-forming Ag halide emulsion layer contains a coupler, I (R1 = substituent, but not H; Q = non-metallic atomic group forming 3-5-membered ring containing ≥ 1 hetero atom; R2 = alkyl, aryl, heterocyclyl; X = H, coupling-off group leaving upon reaction with oxidized developing agent; R1 may form bicycylalkyl by combining with Q). The title preparation comprises exposing said photog. material with red, green, and blue light by using color-separated cyan, magenta, and yellow dot-image films, and effecting color development.


IT 163392-34-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(direct pos. silver halide photog. material and preparation of color proof)

RN 163392-34-5 CAPLUS

CN Carbamic acid, [3-[5-[[4-[[2-[(dodecylsulfonyl)amino]benzoyl]amino]-2,5-dihydroxyphenyl]thio]-1H-tetrazol-1-yl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




IT 163392-33-4

RL: TEM (Technical or engineered material use); USES (Uses)
(direct pos. silver halide photog. material and preparation of color proof)

RN 163392-33-4 CAPLUS

CN Benzamide, 2-[(dodecylsulfonyl)amino]-N-[4-[[1-[3-[[[3-[[[4-(2-formylhydrazino)phenyl]amino]sulfonyl]phenyl]amino]carbonyl]amino]phenyl]-1H-tetrazol-5-yl]thio]-2,5-dihydroxyphenyl]- (9CI) (CA INDEX NAME)



L35 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:576647 CAPLUS Full-text

DOCUMENT NUMBER: 122:326381

TITLE: Color photographic material with improved color density

INVENTOR(S): Ooki, Nobutaka; Fukagawa, Nobutaka; Asanuma, Naoki

PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 71 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

JP 07056293
 PRIORITY APPLN. INFO.:
 GI

A


19950303

JP 1993-204326

JP 1993-204326

19930818

19930818



AB The title photog. material contains I [R1 = H, alkyl; R2 = alkyl, aryl, heterocyclyl, amino, alkoxy; X = CO, SO₂, COCO; R3, R4 = H, group with Hammett substituent constant (σ_p) ≤ 0.3 ; B = group releasing FA following separation from oxidized hydroquinone nucleus; m = 0, 1, 2; FA = fogging agent or development promoter residue; A, A' = H, group-removable by alkali; R2 and R3 may combine to form a heterocycle]. A development inhibitor is released via the redox reaction with oxidized developing agent, and high clarity images are produced.

IT 163392-42-5

RL: DEV (Device component use); USES (Uses)

(development promoter-releasing compound; color photog. material containing)


RN 163392-42-5 CAPLUS

CN Acridinium, 7-[[[[[5-[[4-[[2-[(hexadecylsulfonyl)amino]benzoyl]amino]-2,5-dihydroxyphenyl]thio]-1,3,4-thiadiazol-2-yl]thio]acetyl]amino]-1,2,3,4-tetrahydro-10-(2-propynyl)-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 163392-41-4


CMF C49 H61 N6 O6 S4



CM 2

CRN 37181-39-8

CMF C F3 O3 S




IT 163392-33-4P

RL: DEV (Device component use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)

(development promoter-releasing compound; color photog. material containing)

RN 163392-33-4 CAPLUS

CN Benzamide, 2-[(dodecylsulfonyl)amino]-N-[4-[[1-[3-[[[3-[[4-(2-formylhydrazino)phenyl]amino]sulfonyl]phenyl]amino]carbonyl]amino]phenyl]-1H-tetrazol-5-yl]thio]-2,5-dihydroxyphenyl]- (9CI) (CA INDEX NAME)




IT 163392-34-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(photog. development promoter-releasing compound from)

RN 163392-34-5 CAPLUS


CN Carbamic acid, [3-[5-[[4-[[2-[(dodecylsulfonyl)amino]benzoyl]amino]-2,5-dihydroxyphenyl]thio]-1H-tetrazol-1-yl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



L35 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1995:520424 CAPLUS Full-text
 DOCUMENT NUMBER: 122:265383
 TITLE: Preparation of 3-(aminophenyl)-1,2,4-triazole derivatives as herbicides
 INVENTOR(S): Mizukai, Muneharu; Sano, Hiromi; Wada, Kunio; Pponma, Toyokuni; Kadotani, Junji; Endo, Takeshi
 PATENT ASSIGNEE(S): Sankyo Co, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 38 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06345743	A	19941220	JP 1994-72082	19940411
PRIORITY APPLN. INFO.:			JP 1994-72082	A 19940411
			JP 1993-84793	19930412
OTHER SOURCE(S):	MARPAT	122:265383		

GI



AB The title compds. [I; R1 = (halo)alkyl, mono- or di-lower alkylamino, Ph, CH2Ph, furyl, thienyl; R2 = H, R1SO2, lower alkyl, lower alkoxy-lower alkyl, lower alkylthio-lower alkyl, lower alkylsulfonyl-lower alkyl, lower alkenyl, lower alkynyl; wherein k = 1,2; R3 = H, lower (halo)alkyl, , lower alkoxy-lower alkyl, lower alkylthio-lower alkyl, lower alkylsulfonyl-lower alkyl, lower (halo)alkenyl, lower alkynyl, Ph, CH2Ph, aliphatic acyl, lower alkylsulfonyl; Y = O, S(O)m; wherein m = 0,1,2; R4 = H, lower (halo)alkyl, cycloalkyl, lower alkoxy-lower alkyl; X = halo, lower alkyl, lower alkoxy-lower alkyl, lower (halo)alkoxy, lower (halo)alkylthio, lower alkylsulfonyl, cyano, NO2; n = 0, 1-3] are prepared Thus, 3-methylthio-4-methyl-5-(3-methyl-4-nitrophenyl)-1,2,4-triazole was reduced by SnCl2/concentrated HCl in EtOH to


give 68.9% 3-methylthio-4-methyl-5- (4-amino-3-methylphenyl)-1,2,4-triazole which was reacted with MeSO₂Cl/Et₃N in CH₂Cl₂ to give 100% title compound I [(R1SO₂NR₂)_k = 4-N(SO₂Me)₂, X_n = 3-Me, Y-R₃ = SMe, R₄ = Me]. Another title compound I [(R1SO₂NR₂)_k = 5-NSO₂Me, X_n = 2,4-Cl₂, Y-R₃ = OEt, R₄ = Me] at 20 g/are preemergence inhibited 91-100% the growth of Echinochloa crus-galli, broad-leaved weed, Scirpus juncooides, Cyperus serotinus, and Eleocharis kuroguwai in flooded paddy soil.

IT 162692-01-5P 162692-02-6P 162692-03-7P
162692-04-8P 162692-05-9P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of phenyltriazole derivs. as herbicides)


RN 162692-01-5 CAPLUS

CN Methanesulfonamide, N-[4-methyl-2-[4-methyl-5-(methylsulfonyl)-4H-1,2,4-triazol-3-yl]phenyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 162692-02-6 CAPLUS

CN Methanesulfonamide, N-[4-methyl-2-[4-methyl-5-(methylsulfonyl)-4H-1,2,4-triazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 162692-03-7 CAPLUS

CN Methanesulfonamide, N-[5-chloro-2-[4-methyl-5-(methylsulfonyl)-4H-1,2,4-triazol-3-yl]phenyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 162692-04-8 CAPLUS

CN Methanesulfonamide, N-[5-chloro-2-[4-methyl-5-(methylsulfonyl)-4H-1,2,4-triazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 162692-05-9 CAPLUS

CN Methanesulfonamide, N-[4-chloro-2-[4-methyl-5-(methylsulfonyl)-4H-1,2,4-triazol-3-yl]phenyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



L35 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:266981 CAPLUS Full-text

DOCUMENT NUMBER: 122:68175

TITLE: Silver halide color photographic material with high sensitivity and pressure resistance

INVENTOR(S): Kobayashi, Hidetoshi

PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 67 pp.

CODEN: JKXXAF



DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06118587	A	19940428	JP 1992-288153	19921005
PRIORITY APPLN. INFO.:			JP 1992-288153	19921005

GI




AB In the title photog. material comprising ≥ 1 photosensitive Ag halide emulsion layer on a support, $\geq 50\%$ of projected area is caused by tabular Ag halide grains with the aspect ratio of ≥ 2 and with dislocations, and ≥ 1 of hydrophilic colloidal layer contains ≥ 1 cyan coupler, I or II [Za = NH, CH(R13); Zb, Zc = C(R14); N; R11-13 = electron-accepting group; R14, R21 = H, substituent; R22 = substituent; Z2 = nonmetallic group forming N-containing 6-membered group; X1,2 = H, coupling-off group released upon reaction with oxidized aromatic primary amine developing agent].

IT 151645-19-1

RL: DEV (Device component use); USES (Uses)
 (cyan coupler; hydrophilic colloidal layers of photog. materials)

RN 151645-19-1 CAPLUS

CN Pyrrolo[1,2-a]-1,3,5-triazine-7-carboxylic acid, 2-[2-[[[2-butoxy-5-(1,1,3,3-tetramethylbutyl)phenyl]sulfonyl]amino]phenyl]-6-[(2-carboxyethyl)thio]-8-cyano-1,4-dihydro-4-oxo-, 7-ethyl ester (9CI) (CA INDEX NAME)




L35 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1994:689540 CAPLUS Full-text
 DOCUMENT NUMBER: 121:289540
 TITLE: Silver halide color photographic photosensitive material

INVENTOR(S): Mizukura, Noboru
 PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 25 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06167782	A	19940614	JP 1992-320424	19921130
PRIORITY APPLN. INFO.:			JP 1992-320424	19921130
OTHER SOURCE(S):	MARPAT	121:289540		

GI



I


AB The title photog. materials comprise blue-, green-, and red-sensitive Ag halide emulsion layers on a support and contain ≥ 1 phenol derivative I (R1 = alkyl, alkenyl, alkynyl, cycloalkyl, aryl; R2 = substituent; R3 = aryl; X = bond, O, S, SO, SO2, CO2, CONR4, SO3, SO2NR4, NR5; R4, R5 = no definition given; Z = H, leaving group in coupling reaction; l = 0-4) as a coupler and ≥ 1 R11CR12R13OH (R11 = alkyl, alkenyl, aryl; R12, R13 = H, alkyl, alkenyl, aryl; the total C number of R11-13 is ≥ 10) as a non-coloring compound in ≥ 1 of the red-sensitive layer(s). The materials show good coloring properties and high photosensitivity. Thus, a color photog. film was prepared by using low and high sensitive red-sensitive Ag(Br, I) emulsion layers containing I [R1 = CH(C6H13)C8H17, R2 = H; R3 = C6H4CN-4, X = NHCO; Z = Cl] and n-C16H33OH.

IT 137558-53-3

RL: TEM (Technical or engineered material use); USES (Uses)
 (photog. coupler, red-sensitive layer containing, with high photosensitivity)

RN 137558-53-3 CAPLUS

CN Benzamide, N-[4-[[[4-(butylsulfonyl)phenyl]amino]carbonyl]amino]-3-hydroxyphenyl]-2-[(dodecylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L35 ANSWER 37 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1994:667650 CAPLUS Full-text
 DOCUMENT NUMBER: 121:267650
 TITLE: Silver halide photographic materials containing
 compound capable of releasing bleach promoting agents
 INVENTOR(S): Asanuma, Naoki; Ooki, Nobutaka; Hirano, Shigeo;
 Matsumoto, Keisuke
 PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 40 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06067375	A	19940311	JP 1992-238927	19920815
PRIORITY APPLN. INFO.:			JP 1992-238927	19920815

AB The title photog. materials comprise a compound, (RED)-{(TIME)n-S-R-L-Sol}m
 [RED = group capable of being oxidized via reaction with oxidized developing
 agent and releasing the rest of the group; R = alkylene; L = divalent bonding
 group, single bonding group; Sol = water-soluble moiety; n = 0, 1; m≥2]
 capable of releasing a bleach promoting agent.

IT **158807-95-5**
 RL: DEV (Device component use); MOA (Modifier or additive use); USES
 (Uses)
 (silver halide photog. material containing bleach promoting agent)

RN 158807-95-5 CAPLUS


CN Benzamide, N-[2,5-dihydroxy-3,4-bis[(8-hydroxy-3-oxooctyl)thio]phenyl]-2-
 [(hexadecylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L35 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1994:65793 CAPLUS Full-text
 DOCUMENT NUMBER: 120:65793
 TITLE: Silver halide color photosensitive material
 INVENTOR(S): Yamakawa, Kazuyoshi; Sato, Kozo
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 81 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 556700	A1	19930825	EP 1993-102017	19930209
EP 556700	B1	19960515		
R: DE, FR, GB, NL				
JP 05232648	A	19930910	JP 1992-69854	19920219
JP 2779728	B2	19980723		
PRIORITY APPLN. INFO.:			JP 1992-69854	A 19920219
OTHER SOURCE(S):	MARPAT 120:65793			
GI				




AB The title material comprises a cyan coupler from I [R1 = H, substituent; R2 = substituent; X = H, group releasable on coupling reaction with an oxidation product of the developer; Z1 = nonmetallic atoms necessary to form 5- or 6-membered N-containing ring which has Z1 dissociative group, Z1 can not be -CONRCONH-; R = substituent]. The photog. material forms a dye which has superior heat resistance and that will not fade away in a reducing environment.

IT 151645-19-1

RL: TEM (Technical or engineered material use); USES (Uses)
 (photog. cyan coupler)

RN 151645-19-1 CAPLUS


CN Pyrrolo[1,2-a]-1,3,5-triazine-7-carboxylic acid, 2-[2-[[[2-butoxy-5-(1,1,3,3-tetramethylbutyl)phenyl]sulfonyl]amino]phenyl]-6-[(2-carboxyethyl)thio]-8-cyano-1,4-dihydro-4-oxo-, 7-ethyl ester (9CI) (CA INDEX NAME)



DOCUMENT NUMBER: 120:41889
 TITLE: Silver halide color photographic material
 INVENTOR(S): Suzuki, Makoto; Takahashi, Osamu; Shimada, Yasuhiro;
 Matsuoka, Koushin; Yoshioka, Yasuhiro
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl.; 86 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 545300	A1	19930609	EP 1992-120280	19921127
EP 545300	B1	19950719		
R: DE, FR, GB, NL				
JP 05202004	A	19930810	JP 1992-70020	19920221
JP 05204107	A	19930813	JP 1992-70002	19920221
JP 2699237	B2	19980119		
US 5348847	A	19940920	US 1992-982445	19921127
PRIORITY APPLN. INFO.:			JP 1991-311212	A 19911127
			JP 1991-335861	A 19911127
			JP 1992-70002	A 19920221

OTHER SOURCE(S): MARPAT 120:41889
 GI



AB The title material comprises ≥ 1 layer containing a cyan coupler from I, II, and III [R11 = alkyl, alkoxy, aryl, aryloxy; R21, R22, R32, R43 = substituent; R12 = aliphatic, aryl, heterocyclyl, alkoxy, aryloxy, acylamino, heterocyclic amino, heterocyclic oxy; p = 0-4; R13, R23, R33 = H, substituent provided that the total of Taft's substituent constant σ value of all of them is ≥ 1.5 ; X1-X3 = H, group capable of splitting off by a coupling reaction; all of the above groups may be divalent and form a dimer or higher (co)polymer]. The material forms a color image with good color hue and fastness. It is hardly fogged and the dyes formed from the coupler hardly associate with each other in the material.


IT 151019-81-7

RL: TEM (Technical or engineered material use); USES (Uses)

(photog. cyan coupler)

RN 151019-81-7 CAPLUS

CN 1H-Pyrrolo[1,2-b][1,2,4]triazole-7-carboxylic acid, 5-[[2-(acetyl-amino)phenyl]thio]-6-cyano-2-[2-[[[2-[2-(hexyloxy)ethoxy]-5-(1,1,3,3-tetramethylbutyl)phenyl]sulfonyl]amino]phenyl]-, 2-(diethylamino)-2-oxoethyl ester (9CI) (CA INDEX NAME)



L35 ANSWER 40 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1994:41858 CAPLUS Full-text

DOCUMENT NUMBER: 120:41858

TITLE: Color photographic material with good sharpness and low minimum density

INVENTOR(S): Nagaoka, Satoshi; Hirano, Shigeo

PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 71 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05027380	A	19930205	JP 1991-205624	19910723
PRIORITY APPLN. INFO.: GI			JP 1991-205624	19910723



I



II

AB In the title color photog. material having ≥ 1 Ag halide emulsion layer on its support, ≥ 1 component layer comprises monodisperse Ag halide grains and ≥ 1

component layer contains I [R11 = NR14R16CONR15, R14OCONR15, R14SO2NR15, NR14R16SO2NR15, R17CONH; R14 = alkyl, alkenyl, alkynyl, aryl, heterocyclyl; R15,16 = H, alkyl, aryl; R17 = alkyl, alkynyl, aryl, heterocyclyl; R12,13 = H, substituent with Hammett substituent constant ≤ 0.3 ; B = group for releasing X; X = development inhibitor residue; k = integer; A, A' = H, alkali-removable group] and/or II [Q1 = atoms required to complete a ≥ 5 -membered heterocyclic ring; R21 = substituent; B, X, k, A, a' = same as those in I].


IT 151691-43-9

RL: USES (Uses)

(color photog. material containing)

RN 151691-43-9 CAPLUS


CN Benzamide, N-[2,5-dihydroxy-4-[[5-(methylthio)-1,3,4-thiadiazol-2-yl]thio]phenyl]-2-[(hexadecylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L35 ANSWER 41 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1993:505757 CAPLUS Full-text
 DOCUMENT NUMBER: 119:105757
 TITLE: Silver halide photographic material
 INVENTOR(S): Hirano, Shigeo; Hanaki, Koichi; Inoue, Akiyuki
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 39 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04285955	A	19921012	JP 1991-73672	19910314
PRIORITY APPLN. INFO.:			JP 1991-73672	19910314

GI



I


AB In the title material comprising a support having thereon one or more silver halide emulsion layers and hydrophilic colloid layers, the emulsion layers or hydrophilic colloid layers contain a hydroquinone derivative Compound I is an example of the hydroquinone derivative The title material gives high-quality images.

IT 146625-47-0 146897-72-5

RL: TEM (Technical or engineered material use); USES (Uses)
(photog. materials containing)


RN 146625-47-0 CAPLUS

CN Benzamide, N-[2,5-dihydroxy-4-(octylthio)phenyl]-5-
[(dodecylamino)sulfonyl]-2-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 146897-72-5 CAPLUS

CN Benzenesulfonic acid, 4-[[4-[[2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxobutyl]amino]-2-[(methylsulfonyl)amino]benzoyl]amino]-2,5-dihydroxy-, monosodium salt (9CI) (CA INDEX NAME)



L35 ANSWER 42 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:179908 CAPLUS Full-text

DOCUMENT NUMBER: 118:179908

TITLE: Direct-positive color photographic material and image formation method using the material

INVENTOR(S): Inoue, Akiyuki; Hirano, Shigeo; Hanaki, Koichi

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 38 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04285948	A	19921012	JP 1991-73690	19910314
PRIORITY APPLN. INFO.:			JP 1991-73690	19910314


GI



- AB Silver halide emulsion layers or hydrophilic colloid layers in the title material contain a compound represented by I. For I, R1, R2 = H or a group to be cleaved from O (during development) to release OH; R3 = alkyl, aryl, alkenyl, etc.; R4, R5 = a substituent group on benzene ring; m = 0 to 4; n = 0 to 3; L = a divalent linking group; t = 0 to 3. The title image formation method comprises the development of the title material by the use of a phenylenediamine developing agent. The title material provides low min. d.
- IT **146625-47-0 146897-72-5**
 RL: TEM (Technical or engineered material use); USES (Uses)
 (photog. materials containing)
- RN 146625-47-0 CAPLUS
- CN Benzamide, N-[2,5-dihydroxy-4-(octylthio)phenyl]-5-
 [(dodecylamino)sulfonyl]-2-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



- RN 146897-72-5 CAPLUS
- CN Benzenesulfonic acid, 4-[[4-[[2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxobutyl]amino]-2-[(methylsulfonyl)amino]benzoyl]amino]-2,5-dihydroxy-, monosodium salt (9CI) (CA INDEX NAME)



● Na

L35 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1993:157712 CAPLUS Full-text
 DOCUMENT NUMBER: 118:157712
 TITLE: Silver halide color photographic material
 INVENTOR(S): Yoshioka, Yasuhiro; Sakai, Shuichi
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 90 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04275547	A	19921001	JP 1991-61039	19910304
PRIORITY APPLN. INFO.:			JP 1991-61039	19910304

GI For diagram(s), see printed CA Issue.


AB In the title material comprising a support having thereon a cyan coupler-containing silver halide emulsion layer, a magenta coupler-containing silver halide emulsion layer, and a yellow coupler-containing silver halide emulsion layer, the cyan coupler-containing emulsion layer contains an ureidophenol coupler. The yellow coupler-containing emulsion layer contains an acylacetamide coupler having an acyl group represented by I. For I, R1 = monovalent group; Q = nonmetallic atoms which, together with C, form a 3- to 5-membered hydrocarbon or heterocyclic ring. The title material shows high sensitivity.

IT 137558-53-3

RL: TEM (Technical or engineered material use); USES (Uses)
 (photog. coupler)


RN 137558-53-3 CAPLUS

CN Benzamide, N-[4-[[[4-(butylsulfonyl)phenyl]amino]carbonyl]amino]-3-hydroxyphenyl]-2-[(dodecylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L35 ANSWER 44 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1992:265448 CAPLUS Full-text
 DOCUMENT NUMBER: 116:265448
 TITLE: Silver halide color photographic material
 INVENTOR(S): Naito, Hideki
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 30 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03288849	A	19911219	JP 1990-90398	19900406
PRIORITY APPLN. INFO.: GI			JP 1990-90398	19900406



I


AB In the title material comprising a support having thereon photog. layers which include one or more Ag halide emulsion layers, the said photog. layers contain at least one cyan coupler represented by general structure I (R1 = alkyl, alkenyl, cycloalkyl, etc.; X = a single bond, O, S, etc.; R2 = a substituent on benzene ring; R3 = aryl; Z = H, a group to be released upon coupling reaction; 1 = 0 to 4). For the title material, the total thickness of all hydrophilic colloid layers (on the support side which has emulsion layers) is $\leq 18 \mu\text{m}$. The title material gives high-quality images.

IT 137558-53-3

RL: TEM (Technical or engineered material use); USES (Uses)
 (photog. coupler)



RN 137558-53-3 CAPLUS

CN Benzamide, N-[4-[[[4-(butylsulfonyl)phenyl]amino]carbonyl]amino]-3-hydroxyphenyl]-2-[(dodecylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L35 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1991:666707 CAPLUS Full-text
 DOCUMENT NUMBER: 115:266707
 TITLE: Silver halide photographic photosensitive materials
 INVENTOR(S): Tsukahara, Jiro; Kobayashi, Hidetoshi
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 79 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 432804	A2	19910619	EP 1990-124261	19901214
EP 432804	A3	19920226		
EP 432804	B1	19960703		
R: DE, FR, GB, NL				
JP 03185441	A	19910813	JP 1989-325012	19891215
JP 2537096	B2	19960925		
US 5210011	A	19930511	US 1990-625481	19901211
PRIORITY APPLN. INFO.:			JP 1989-325012	A 19891215
OTHER SOURCE(S):	MARPAT 115:266707			
GI				




AB The title material comprises a support having thereon at least one Ag halide emulsion layer and contains at least one cyan dye forming coupler represented by I [R1 = (substituted) alkyl, alkenyl, alkynyl, etc.; X1 = single bond, O, S, SO, etc.; R2 = substituent on benzene ring; l = 0 to 4; R3 = (substituted) aryl; Z1 = H, coupling-off group] and at least one cyan dye forming coupler represented by II (R1 = CONR4R5, SO2NR4R5, NHCOR4, etc.; R2 = substituent on naphthalene ring; l = 0 to 3; R3 = substituent; X1 = coupling-off group; R4, R5 = H, alkyl, aryl, etc.; R2 and R3 or R3 and X1 may combine and form a ring; and dimers or larger oligomers formed by joining together via di- or higher valent groups at R1, R2, R3, or X1) in a layer on the said support. The title material has a high coupling reactivity and a high maximum color d.

IT 137558-53-3

RL: TEM (Technical or engineered material use); USES (Uses)
(photog. coupler)

RN 137558-53-3 CAPLUS

CN Benzamide, N-[4-[[[4-(butylsulfonyl)phenyl]amino]carbonyl]amino]-3-hydroxyphenyl]-2-[(dodecylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L35 ANSWER 46 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1991:666698 CAPLUS Full-text

DOCUMENT NUMBER: 115:266698

TITLE: Silver halide color photographic photosensitive materials

INVENTOR(S): Tsukahara, Jiro; Kobayashi, Hidetoshi

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 85 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 434028	A2	19910626	EP 1990-124768	19901219
EP 434028	A3	19920226		
R: DE, FR, GB, NL				
JP 03191345	A	19910821	JP 1989-330766	19891220
US 5192651	A	19930309	US 1990-630257	19901219
PRIORITY APPLN. INFO.:			JP 1989-330766	A 19891220
OTHER SOURCE(S):	MARPAT 115:266698			

GI



I



II

AB The title material comprises a support having thereon at least one silver halide emulsion layer and contains at least one cyan dye forming coupler represented by formula I and at least one cyan dye forming coupler represented by formula II in proportions, resp., of 20 to 99 weight% and 1 to 80 weight%. For I and II, R1 = (substituted) alkyl, alkenyl, alkynyl, etc.; X1 = single bond, O, S, SO, etc.; R2 = substituent on benzene ring; l = 0 to 4; R3 = (substituted) aryl; R4, R5 = H, alkyl, alkenyl, alkynyl, etc.; Z1 = H, or coupling-off group (sic). I and II have a high coupling reactivity. The title material has a high maximum color d. (Dmax).


IT 137558-53-3

RL: USES (Uses)

(cyan coupler, in photog. material)

RN 137558-53-3 CAPLUS

CN Benzamide, N-[4-[[[4-(butylsulfonyl)phenyl]amino]carbonyl]amino]-3-hydroxyphenyl]-2-[(dodecylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L35 ANSWER 47 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1991:502709 CAPLUS Full-text

DOCUMENT NUMBER: 115:102709

TITLE: Silver halide color photographic material containing pyrazoloazole-type cyan coupler

INVENTOR(S): Kita, Hiroshi; Kida, Shuji; Kaneko, Yutaka; Hirabayashi, Shigeto

PATENT ASSIGNEE(S): Konica Co., Japan


SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02201358	A	19900809	JP 1989-21748	19890130
PRIORITY APPLN. INFO.: GI			JP 1989-21748	19890130



AB A red-sensitive Ag halide emulsion layer of the title photog. material contains a coupler I (R = electron acceptor or moiety forming H bond; A = arylene; X = moiety which is bonded with C at coupling position via O, S, or N and is capable of being released by reaction with oxidized product of a color developing agent; Y = H or moiety released during development). This photog. material containing the cyan coupler with good spectral characteristics gives improved color d. and sharp and stable cyan images.



IT 135020-03-0

RL: USES (Uses)

(cyan coupler, red-sensitive photog. emulsion layer containing)

RN 135020-03-0 CAPLUS

CN Ethanesulfonamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[5-(1,1-dimethylethoxy)-2-[7-[(2-hydroxyethyl)thio]-6-(trifluoromethyl)-1H-pyrazolo[1,5-b][1,2,4]triazol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



L35 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1991:471636 CAPLUS Full-text

DOCUMENT NUMBER: 115:71636

TITLE: Preparation of [(heteroaryloxyphenylcarbamoyl)phenyl]a
 minosulfonylbenzenes as anthelmintics

INVENTOR(S): Maienfisch, Peter; Hildenbrand, Christof; Gehret, Jean

PATENT ASSIGNEE(S): Claude
 SOURCE: Ciba-Geigy A.-G., Switz.
 Eur. Pat. Appl., 37 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 420804	A2	19910403	EP 1990-810710	19900918
EP 420804	A3	19911127		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5081125	A	19920114	US 1990-586176	19900919
JP 03123773	A	19910527	JP 1990-248968	19900920
CA 2026037	A1	19910327	CA 1990-2026037	19900924
HU 54986	A2	19910429	HU 1990-6028	19900924
AU 9063201	A	19910411	AU 1990-63201	19900925
AU 627075	B2	19920813		
ZA 9007637	A	19910529	ZA 1990-7637	19900925
DD 299179	A5	19920402	DD 1990-344230	19900926
US 5132314	A	19920721	US 1991-783433	19911025
PRIORITY APPLN. INFO.:			CH 1989-3481	A 19890926
			US 1990-586176	A3 19900919
OTHER SOURCE(S):	MARPAT 115:71636			
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; R1 = H, halo, (halo)alkyl, thioalkyl, NO2, alkoxy, SOnR; R = alkyl, Ph; n = 0-2; R2 = H, halo, (halo)alkyl, (halo)alkoxy; R3, R4 = H, Me, Et; R5, R6 = H, halo, alkyl; R7 = H, halo, (halo)alkyl, (halo)alkoxy, NO2; R8, R9 = H, halo, (halo)alkyl, (halo)alkoxy; R10, R11 = H, halo, (halo)alkyl, alkylthio, cycloalkyl, cyano; R12 = H, halo; X = CH, N], were prepared Thus, a mixture of 5-chloro-2-nitrobenzoyl chloride (preparation given), 4-[3-chloro-5-trifluoromethylpyridyl-2-oxy]aniline, and Et3N was stirred 2 h in CH2Cl2 to give the corresponding anilide, which was reduced to the amine using Raney Ni/H in THF. The amine was stirred 16 h with 4-ClC6H4SO2Cl in pyridine to give title compound II which at 20 mg/kg orally in sheep gave a >90% reduction in nematode (e.g., Haemonchus contortus, Trichostrongylus colubriformis) nos.

IT **135078-96-5P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as anthelmintic)

RN 135078-96-5 CAPLUS


CN Benzamide, 3,5-dichloro-2-[[4-(4-chlorophenyl)sulfonyl]amino]-N-[4-[[6-methyl-2-(methylthio)-4-pyrimidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



L35 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:45610 CAPLUS Full-text
 DOCUMENT NUMBER: 112:45610
 TITLE: Photographic material containing
 thiocarbonylthiophenol cyan coupler
 INVENTOR(S): Ishii, Fumio; Uchida, Taku; Miura, Akio; Tsuruta,
 Mayumi
 PATENT ASSIGNEE(S): Konica Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01206338	A	19890818	JP 1988-32095	19880215
PRIORITY APPLN. INFO.:			JP 1988-32095	19880215

GI



I

AB The title material contains a cyan coupler CpSCSJlRl [Cp = residue of cyan coupler after removal of H from an active site; Rl = (substituted) alkyl, aryl, heterocycle; J = O, S; l = 0, 1]. The material gives an image with high sensitivity and high color d. in using a fatigued bleaching bath. Thus, a red-sensitive Ag(Br, I) emulsion containing a cyan coupler I was applied onto a polyester support to give the title material.



IT **124675-36-1**

RL: USES (Uses)

(cyan coupler, for silver halide photog. emulsion)

RN 124675-36-1 CAPLUS


CN Carbonotrithioic acid, 2-[[2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxopropyl]amino]-4-hydroxy-5-[[2-[(phenylsulfonyl)amino]benzoyl]amino]phenyl 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



L35 ANSWER 50 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1989:431238 CAPLUS Full-text
DOCUMENT NUMBER: 111:31238
TITLE: Silver halide color photographic light-sensitive
material containing cyan coupler
INVENTOR(S): Tachibana, Kimie; Kaneko, Yutaka
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Eur. Pat. Appl., 81 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 287265	A1	19881019	EP 1988-303035	19880406
EP 287265	B1	19911016		
R: DE, FR, GB, IT, NL				
JP 63250649	A	19881018	JP 1987-85510	19870407
JP 2526243	B2	19960821		
JP 63250650	A	19881018	JP 1987-85511	19870407
JP 2535529	B2	19960918		
JP 63280247	A	19881117	JP 1987-114838	19870513
US 4916051	A	19900410	US 1988-177987	19880405
PRIORITY APPLN. INFO.:			JP 1987-85510	A 19870407
			JP 1987-85511	A 19870407
			JP 1987-114838	A 19870513

GI




AB Cyan dye-forming photog. couplers of the formulas I-VI (R_1 - R_5 = H, a substituent, or a group having an active H atom capable of forming an active H bond; Y, Y_1 , Y_2 = H or a substituent; X = H or a substituent capable of being split off upon reaction with the oxidized product of a color developing agent; $n = 0-4$), which gives clear cyan dye images with excellent spectral absorption, are described. Thus, a polyethylene-coated paper support was coated with a red-sensitive gelatin-Ag(Br,Cl) emulsion containing VII, dried, a protective layer added, and the material exposed and color developed to show an image with a λ_{max} of 637 nm and excellent resistance to heat and moisture.

IT 119551-28-9

RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler)

RN 119551-28-9 CAPLUS

CN 1H-Pyrazolo[1,5-b][1,2,4]triazole-6-sulfonamide, N-(4-acetylphenyl)-2-[2-[[2-[2-butoxy-5-(1,1,3,3-tetramethylbutyl)phenoxy]ethyl]sulfonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L35 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1974:14730 CAPLUS Full-text

DOCUMENT NUMBER: 80:14730

TITLE: Two-equivalent sulfonamido photographic couplers

INVENTOR(S): Salminen, Ilmari Fritiof; Loria, Anthony
 PATENT ASSIGNEE(S): Eastman Kodak Co.
 SOURCE: U.S., 11 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3737316	A	19730605	US 1971-176684	19710831
PRIORITY APPLN. INFO.:			US 1971-176684	A 19710831

GI For diagram(s), see printed CA Issue.


AB Thirteen p-sulfonamidophenols (I; R = Me, H, OMe, acylamino; R1 = H, Me; R2 = Ph, nitrophenyl, 1-ClOH7, Me; R3 = H, OMe, acylamino; R4 = Me, H, CHMe2), useful as photog. couplers, are prepared by sulfonylation of aminophenols. Similarly prepared are four 4-sulfonamidonaphthols (II; R = H, Me, CONHBu; R1 = Ph, 1-ClOH7) which can also be used as cyan photog. couplers.

IT 50994-53-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (photog. cupler, preparation of)

RN 50994-53-1 CAPLUS

CN Benzenesulfonyl chloride, 3-[[5-hydroxy-4-[(1-oxooctadecyl)amino]-2-[(phenylsulfonyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



=> d his full

(FILE 'HOME' ENTERED AT 12:30:25 ON 30 MAR 2007)

FILE 'CAPLUS' ENTERED AT 12:30:54 ON 30 MAR 2007

E US2004-816143/APPS

L1 1 SEA ABB=ON PLU=ON US2004-816143/AP
D SCA
SEL RN

FILE 'REGISTRY' ENTERED AT 12:31:52 ON 30 MAR 2007

L2 165 SEA ABB=ON PLU=ON (107143-77-1/BI OR 110-91-8/BI OR 123-75-1/
BI OR 123-90-0/BI OR 2516-95-2/BI OR 254876-98-7/BI OR
254876-99-8/BI OR 254877-00-4/BI OR 254877-01-5/BI OR 254877-02
-6/BI OR 254877-03-7/BI OR 254877-04-8/BI OR 254877-05-9/BI OR
254877-06-0/BI OR 254877-07-1/BI OR 254877-08-2/BI OR 254877-09
-3/BI OR 254877-10-6/BI OR 254877-11-7/BI OR 254877-12-8/BI OR
254877-13-9/BI OR 254877-14-0/BI OR 254877-15-1/BI OR 254877-16
-2/BI OR 254877-17-3/BI OR 254877-18-4/BI OR 254877-19-5/BI OR
254877-20-8/BI OR 254877-21-9/BI OR 254877-22-0/BI OR 254877-23
-1/BI OR 254877-24-2/BI OR 254877-25-3/BI OR 254877-26-4/BI OR
254877-27-5/BI OR 254877-28-6/BI OR 254877-29-7/BI OR 254877-30
-0/BI OR 254877-31-1/BI OR 254877-32-2/BI OR 254877-33-3/BI OR
254877-34-4/BI OR 254877-35-5/BI OR 254877-36-6/BI OR 254877-37
-7/BI OR 254877-38-8/BI OR 254877-39-9/BI OR 254877-40-2/BI OR
254877-41-3/BI OR 254877-42-4/BI OR 254877-43-5/BI OR 254877-44
-6/BI OR 254877-45-7/BI OR 254877-46-8/BI OR 254877-47-9/BI OR
254877-48-0/BI OR 254877-49-1/BI OR 254877-50-4/BI OR 254877-51
-5/BI OR 254877-52-6/BI OR 254877-53-7/BI OR 254877-54-8/BI OR
254877-55-9/BI OR 254877-56-0/BI OR 254877-57-1/BI OR 254877-58
-2/BI OR 254877-59-3/BI OR 254877-60-6/BI OR 254877-61-7/BI OR
254877-62-8/BI OR 254877-63-9/BI OR 254877-64-0/BI OR 254877-65
-1/BI OR 254877-66-2/BI OR 254877-67-3/BI OR 254877-68-4/BI OR
254877-69-5/BI OR 254877-70-8/BI OR 254877-71-9/BI OR 254877-72
-0/BI OR 254877-74-2/BI OR 254877-76-4/BI OR 254877-77-5/BI OR
254877-78-6/BI OR 254877-79-7/BI OR 254877-80-0/BI OR 254877-81
-1/BI OR 254877-82-2/BI OR 254877-83-3/BI OR 254877-84-4/BI OR
254877-85-5/BI OR 254877-86-6/BI OR 254877-87-7/BI OR 254877-88
-8/BI OR 254877-89-9/BI OR 254877-90-2/BI OR 254877-91-3/BI OR
254877-92-4/BI OR 254877-93-5/BI OR 254877-94-6/BI

FILE 'STNGUIDE' ENTERED AT 12:35:38 ON 30 MAR 2007

FILE 'REGISTRY' ENTERED AT 13:28:30 ON 30 MAR 2007

L3 STRUCTURE UPLOADED
L4 25 SEA SSS SAM L3
L5 2 SEA ABB=ON PLU=ON L4 AND NRRS>1
D SCA
D STAT QUE L4
L6 512 SEA SSS FUL L3
SAVE TEMP L6 WAR143STR3L/A

FILE 'CAPLUS' ENTERED AT 13:30:53 ON 30 MAR 2007

L7 56 SEA ABB=ON PLU=ON L6

FILE 'REGISTRY' ENTERED AT 13:31:02 ON 30 MAR 2007

L8 58 SEA ABB=ON PLU=ON L6 AND NRRS>1
L9 6 SEA ABB=ON PLU=ON L8 AND L2

FILE 'CAPLUS' ENTERED AT 13:39:38 ON 30 MAR 2007
L10 123 SEA ABB=ON PLU=ON SCHINDLER U?/AU
L11 7 SEA ABB=ON PLU=ON SCHONAFINGER K?/AU
L12 315 SEA ABB=ON PLU=ON STROBEL H?/AU
L13 15 SEA ABB=ON PLU=ON L10 AND (L11 OR L12)
L14 3 SEA ABB=ON PLU=ON L11 AND L12
L15 15 SEA ABB=ON PLU=ON (L13 OR L14)
L16 4 SEA ABB=ON PLU=ON (L10 OR L11 OR L12) AND L7
L17 15 SEA ABB=ON PLU=ON (L15 OR L16)

FILE 'REGISTRY' ENTERED AT 13:42:43 ON 30 MAR 2007
L18 2 SEA ABB=ON PLU=ON L6 AND CL=4
D SCA
E "BENZANILIDE, 3,5,5'-TRICHLORO-2'-(P-CHLOROPHENYL)THIO)-2-ME
L19 1 SEA ABB=ON PLU=ON "BENZANILIDE, 3,5,5'-TRICHLORO-2'-(P-CHLOR
OPHENYL)THIO)-2-METHANESULFONAMIDO-"/CN
L20 511 SEA ABB=ON PLU=ON L6 NOT L19

FILE 'CAPLUS' ENTERED AT 13:45:54 ON 30 MAR 2007
L21 55 SEA ABB=ON PLU=ON L20
L*** DEL 0 S L2 AND CL>1

FILE 'REGISTRY' ENTERED AT 13:47:51 ON 30 MAR 2007
L22 59 SEA ABB=ON PLU=ON L2 AND CL>1
L23 408696 SEA ABB=ON PLU=ON MORPHOLIN?/CNS
L24 12 SEA ABB=ON PLU=ON L22 AND L23
D SCA
L25 954420 SEA ABB=ON PLU=ON THIAZOL?/CNS
L26 3 SEA ABB=ON PLU=ON L2 AND L25
D SCA
L27 3 SEA ABB=ON PLU=ON L6 AND L26
L28 4114 SEA ABB=ON PLU=ON NCSC2/ESS AND NC2SC2/ESS
L29 1 SEA ABB=ON PLU=ON L28 AND L6
D SCA
SEL RN
L30 0 SEA ABB=ON PLU=ON 254877-03-7/CRN

FILE 'CAPLUS' ENTERED AT 14:01:25 ON 30 MAR 2007
L31 2 SEA ABB=ON PLU=ON L29
L32 2 SEA ABB=ON PLU=ON (L15 OR L16) AND L31

FILE 'REGISTRY' ENTERED AT 14:03:31 ON 30 MAR 2007

FILE 'CAPLUS' ENTERED AT 14:03:34 ON 30 MAR 2007
D STAT QUE L15
D STAT QUE L16
L33 15 SEA ABB=ON PLU=ON (L15 OR L16)

FILE 'REGISTRY' ENTERED AT 14:06:14 ON 30 MAR 2007
D IDE L29

FILE 'CAPLUS' ENTERED AT 14:06:15 ON 30 MAR 2007
L34 2 SEA ABB=ON PLU=ON L29 AND L33
D IBIB ABS HITRN L33 1-15

FILE 'REGISTRY' ENTERED AT 14:07:44 ON 30 MAR 2007

FILE 'CAPLUS' ENTERED AT 14:07:46 ON 30 MAR 2007
D STAT QUE L21

L35 51 SEA ABB=ON PLU=ON L21 NOT L33
 D IBIB ABS HITSTR L35 1-51

FILE HOME

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Mar 2007 VOL 146 ISS 15
FILE LAST UPDATED: 29 Mar 2007 (20070329/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 MAR 2007 HIGHEST RN 928707-03-3
DICTIONARY FILE UPDATES: 29 MAR 2007 HIGHEST RN 928707-03-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE STNGUIDE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Mar 23, 2007 (20070323/UP).